{"name":"Eli Lilly","slug":"eli-lilly","ticker":"LLY","exchange":"NYSE","domain":"lilly.com","description":"Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.","hq":"Indianapolis, IN","founded":0,"employees":"50000","ceo":"David A. Ricks","sector":"Big Pharma","stockPrice":1008.8,"stockChange":-6.95,"stockChangePercent":-0.68,"marketCap":"$899.6B","metrics":{"revenue":65179000000,"revenueGrowth":55.5,"grossMargin":82.8,"rdSpend":7190800000,"netIncome":20640000000,"cash":5281999872,"dividendYield":0.68,"peRatio":35.8,"fiscalYear":"FY2025"},"revenueBreakdown":[{"name":"Mounjaro","genericName":"TIRZEPATIDE","slug":"tirzepatide","revenue":15530000000,"yoyGrowth":0,"percentOfTotal":42.3},{"name":"Trulicity","genericName":"DULAGLUTIDE","slug":"dulaglutide","revenue":7200000000,"yoyGrowth":0,"percentOfTotal":19.6},{"name":"Verzenio","genericName":"abemaciclib","slug":"abemaciclib","revenue":3700000000,"yoyGrowth":0,"percentOfTotal":10.1},{"name":"Taltz","genericName":"ixekizumab","slug":"ixekizumab","revenue":2700000000,"yoyGrowth":0,"percentOfTotal":7.4},{"name":"Humalog","genericName":"INSULIN LISPRO","slug":"insulin-lispro","revenue":2200000000,"yoyGrowth":0,"percentOfTotal":6},{"name":"Olumiant","genericName":"baricitinib","slug":"baricitinib","revenue":1200000000,"yoyGrowth":0,"percentOfTotal":3.3},{"name":"Prozac","genericName":"fluoxetine","slug":"fluoxetine","revenue":1000000000,"yoyGrowth":0,"percentOfTotal":2.7},{"name":"Cyramza","genericName":"RAMUCIRUMAB","slug":"ramucirumab","revenue":900000000,"yoyGrowth":0,"percentOfTotal":2.5},{"name":"Omvoh","genericName":"MIRIKIZUMAB","slug":"mirikizumab","revenue":800000000,"yoyGrowth":0,"percentOfTotal":2.2},{"name":"Retevmo","genericName":"SELPERCATINIB","slug":"selpercatinib","revenue":700000000,"yoyGrowth":0,"percentOfTotal":1.9},{"name":"Emgality","genericName":"GALCANEZUMAB","slug":"galcanezumab","revenue":500000000,"yoyGrowth":0,"percentOfTotal":1.4},{"name":"Zyprexa","genericName":"olanzapine","slug":"olanzapine","revenue":300000000,"yoyGrowth":0,"percentOfTotal":0.8}],"timeline":[{"date":"1939-01-01","label":"Eramin first approved","drug":"Eramin","drugSlug":"histamine","type":"approval","sentiment":"positive"},{"date":"1941-01-01","label":"Sulfadiazine first approved","drug":"Sulfadiazine","drugSlug":"sulfadiazine","type":"approval","sentiment":"positive"},{"date":"1950-01-01","label":"Quinidine Gluconate first approved","drug":"Quinidine Gluconate","drugSlug":"quinidine-sulfate","type":"approval","sentiment":"positive"},{"date":"1964-01-01","label":"Dymelor first approved","drug":"Dymelor","drugSlug":"acetohexamide","type":"approval","sentiment":"positive"},{"date":"1970-01-01","label":"Kafocin first approved","drug":"Kafocin","drugSlug":"cefaloglycin","type":"approval","sentiment":"positive"},{"date":"1974-01-01","label":"Cephalotin first approved","drug":"Cephalotin","drugSlug":"cefalotin","type":"approval","sentiment":"positive"},{"date":"1978-01-01","label":"Kefadol first approved","drug":"Kefadol","drugSlug":"cefamandole-nafate","type":"approval","sentiment":"positive"},{"date":"1980-01-01","label":"Cinobac first approved","drug":"Cinobac","drugSlug":"cinoxacin","type":"approval","sentiment":"positive"},{"date":"1982-01-01","label":"Humulin first approved","drug":"Humulin","drugSlug":"insulin","type":"approval","sentiment":"positive"},{"date":"1987-12-29","label":"Prozac first approved","drug":"Prozac","drugSlug":"fluoxetine","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Humalog first approved","drug":"Humalog","drugSlug":"insulin-lispro","type":"approval","sentiment":"positive"},{"date":"1997-01-01","label":"Evista first approved","drug":"Evista","drugSlug":"raloxifene","type":"approval","sentiment":"positive"},{"date":"2002-01-01","label":"Strattera first approved","drug":"Strattera","drugSlug":"atomoxetine","type":"approval","sentiment":"positive"},{"date":"2004-08-03","label":"Cymbalta first approved","drug":"Cymbalta","drugSlug":"duloxetine","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Trulicity first approved","drug":"Trulicity","drugSlug":"dulaglutide","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Cyramza first approved","drug":"Cyramza","drugSlug":"ramucirumab","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Portrazza first approved","drug":"Portrazza","drugSlug":"necitumumab","type":"approval","sentiment":"positive"},{"date":"2016-01-01","label":"Taltz first approved","drug":"Taltz","drugSlug":"ixekizumab","type":"approval","sentiment":"positive"},{"date":"2016-01-01","label":"Lartruvo first approved","drug":"Lartruvo","drugSlug":"olaratumab","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Verzenio first approved","drug":"Verzenio","drugSlug":"abemaciclib","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Olumiant first approved","drug":"Olumiant","drugSlug":"baricitinib","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Emgality first approved","drug":"Emgality","drugSlug":"galcanezumab","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Reyvow first approved","drug":"Reyvow","drugSlug":"lasmiditan","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Retevmo first approved","drug":"Retevmo","drugSlug":"selpercatinib","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Ly-Cov016 first approved","drug":"Ly-Cov016","drugSlug":"etesevimab","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Ly-Cov555 first approved","drug":"Ly-Cov555","drugSlug":"bamlanivimab","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Mounjaro first approved","drug":"Mounjaro","drugSlug":"tirzepatide","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Inluriyo first approved","drug":"Inluriyo","drugSlug":"imlunestrant","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Ebglyss first approved","drug":"Ebglyss","drugSlug":"lebrikizumab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-08-31","label":"Cialis Phase 3 readout (Prostate Carcinoma, Erectile Function)","drug":"Cialis","drugSlug":"tadalafil","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-01","label":"Verzenio PHASE3 readout","drug":"Verzenio","drugSlug":"abemaciclib","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-12-01","label":"Cyramza PHASE3 readout","drug":"Cyramza","drugSlug":"ramucirumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-02-01","label":"Retevmo PHASE1,PHASE2 readout","drug":"Retevmo","drugSlug":"selpercatinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-08-01","label":"Inluriyo PHASE3 readout","drug":"Inluriyo","drugSlug":"imlunestrant","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-01","label":"Verzenio PHASE3 readout","drug":"Verzenio","drugSlug":"abemaciclib","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-02-29","label":"Cialis Phase 3 readout (Hypertension, Pulmonary)","drug":"Cialis","drugSlug":"tadalafil","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-30","label":"Zyprexa Phase 3 readout (Standard Quadruple Antiemetic Therapy, Electroacupuncture)","drug":"Zyprexa","drugSlug":"olanzapine","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-05-01","label":"Verzenio PHASE3 readout","drug":"Verzenio","drugSlug":"abemaciclib","type":"phase3_readout","sentiment":"neutral"},{"date":"2038-10-10","label":"Retevmo patent expiry (Compound)","drug":"Retevmo","drugSlug":"selpercatinib","type":"patent_expiry","sentiment":"negative"},{"date":"2038-10-10","label":"Retevmo patent expiry (Formulation)","drug":"Retevmo","drugSlug":"selpercatinib","type":"patent_expiry","sentiment":"negative"},{"date":"2038-12-24","label":"Cialis patent expiry (Formulation)","drug":"Cialis","drugSlug":"tadalafil","type":"patent_expiry","sentiment":"negative"},{"date":"2038-12-24","label":"Cialis patent expiry (Formulation)","drug":"Cialis","drugSlug":"tadalafil","type":"patent_expiry","sentiment":"negative"},{"date":"2038-12-24","label":"Cialis patent expiry (Formulation)","drug":"Cialis","drugSlug":"tadalafil","type":"patent_expiry","sentiment":"negative"},{"date":"2038-12-24","label":"Cialis patent expiry (Formulation)","drug":"Cialis","drugSlug":"tadalafil","type":"patent_expiry","sentiment":"negative"},{"date":"2039-04-10","label":"Retevmo patent expiry (Compound)","drug":"Retevmo","drugSlug":"selpercatinib","type":"patent_expiry","sentiment":"negative"},{"date":"2039-04-10","label":"Retevmo patent expiry (Compound)","drug":"Retevmo","drugSlug":"selpercatinib","type":"patent_expiry","sentiment":"negative"},{"date":"2039-06-14","label":"Mounjaro patent expiry (Method of Use)","drug":"Mounjaro","drugSlug":"tirzepatide","type":"patent_expiry","sentiment":"negative"},{"date":"2039-07-22","label":"Mounjaro patent expiry (Method of Use)","drug":"Mounjaro","drugSlug":"tirzepatide","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Prozac patent cliff ($2.5B at risk)","drug":"Prozac","type":"patent_expiry","sentiment":"negative"},{"date":"2023-06-01","label":"Cymbalta patent cliff ($1.5B at risk)","drug":"Cymbalta","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":24930000000,"percentOfTotal":67.9,"drugCount":65,"colorKey":"oncology","drugs":[{"name":"Mounjaro","genericName":"TIRZEPATIDE","slug":"tirzepatide","indication":"Diabetes mellitus type 2","status":"marketed","revenue":15530000000},{"name":"Trulicity","genericName":"DULAGLUTIDE","slug":"dulaglutide","indication":"Diabetes mellitus type 2","status":"marketed","revenue":7200000000},{"name":"Humalog","genericName":"INSULIN LISPRO","slug":"insulin-lispro","indication":"Diabetes mellitus type 1","status":"marketed","revenue":2200000000},{"name":"Humulin","genericName":"insulin","slug":"insulin","indication":"Diabetes mellitus type 1","status":"marketed"},{"name":"Dymelor","genericName":"ACETOHEXAMIDE","slug":"acetohexamide","indication":"Diabetes mellitus type 2","status":"marketed"},{"name":"Glucagon Hydrochloride Solution","genericName":"Glucagon Hydrochloride Solution","slug":"glucagon-hydrochloride-solution","indication":"Severe hypoglycemia in patients with diabetes mellitus","status":"phase_3"},{"name":"Glucagon IM","genericName":"Glucagon IM","slug":"glucagon-im","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"Glucagon Nasal Powder","genericName":"Glucagon Nasal Powder","slug":"glucagon-nasal-powder","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"Human Insulin Inhalation Powder","genericName":"Human Insulin Inhalation Powder","slug":"human-insulin-inhalation-powder","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Human Insulin Mix 50:50","genericName":"Human Insulin Mix 50:50","slug":"human-insulin-mix-50-50","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Huminsulin Regular","genericName":"Huminsulin Regular","slug":"huminsulin-regular","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro (U100)","genericName":"Insulin Lispro (U100)","slug":"insulin-lispro-u100","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin Lispro Mix50","genericName":"Insulin Lispro Mix50","slug":"insulin-lispro-mix50","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro-aabc","genericName":"Insulin Lispro-aabc","slug":"insulin-lispro-aabc","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro 2 day reservoir in-use","genericName":"Insulin lispro 2 day reservoir in-use","slug":"insulin-lispro-2-day-reservoir-in-use","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"LY2963016","genericName":"LY2963016","slug":"ly2963016","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"LY3537982","genericName":"LY3537982","slug":"ly3537982","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY3650150","genericName":"LY3650150","slug":"ly3650150","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Lispro Mixture Therapy","genericName":"Lispro Mixture Therapy","slug":"lispro-mixture-therapy","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"AM0010","genericName":"AM0010","slug":"am0010","indication":"Type 2 diabetes","status":"phase_2"},{"name":"Analog or Human Insulin","genericName":"Analog or Human Insulin","slug":"analog-or-human-insulin","indication":"Type 1 diabetes","status":"phase_2"},{"name":"Basal Insulin Analog","genericName":"Basal Insulin Analog","slug":"basal-insulin-analog","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Biguanide (BG)","genericName":"Biguanide (BG)","slug":"biguanide-bg","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Biguanides (BG)","genericName":"Biguanides (BG)","slug":"biguanides-bg","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Exenatide once weekly (QW)","genericName":"Exenatide once weekly (QW)","slug":"exenatide-once-weekly-qw","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Exenatide twice daily (BID)","genericName":"Exenatide twice daily (BID)","slug":"exenatide-twice-daily-bid","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Humalog Mix 50","genericName":"Humalog Mix 50","slug":"humalog-mix-50","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Human Regular U-500 Insulin","genericName":"Human Regular U-500 Insulin","slug":"human-regular-u-500-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Human insulin 30/70","genericName":"Human insulin 30/70","slug":"human-insulin-30-70","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Injectable insulin","genericName":"Injectable insulin","slug":"injectable-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Analog Mid Mixture","genericName":"Insulin Analog Mid Mixture","slug":"insulin-analog-mid-mixture","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Aspart 6 Day (6D)","genericName":"Insulin Aspart 6 Day (6D)","slug":"insulin-aspart-6-day-6d","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin Biphasic Aspart 30/70","genericName":"Insulin Biphasic Aspart 30/70","slug":"insulin-biphasic-aspart-30-70","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro 6 Day (6D)","genericName":"Insulin Lispro 6 Day (6D)","slug":"insulin-lispro-6-day-6d","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin Lispro Mix25","genericName":"Insulin Lispro Mix25","slug":"insulin-lispro-mix25","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro Premix","genericName":"Insulin Lispro Premix","slug":"insulin-lispro-premix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro Protamine Suspension","genericName":"Insulin Lispro Protamine Suspension","slug":"insulin-lispro-protamine-suspension","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro low mixture","genericName":"Insulin Lispro low mixture","slug":"insulin-lispro-low-mixture","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin aspart 6 day reservoir in-use","genericName":"Insulin aspart 6 day reservoir in-use","slug":"insulin-aspart-6-day-reservoir-in-use","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin lispro (Humalog)","genericName":"Insulin lispro (Humalog)","slug":"insulin-lispro-humalog","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro 6 day reservoir in-use","genericName":"Insulin lispro 6 day reservoir in-use","slug":"insulin-lispro-6-day-reservoir-in-use","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin lispro A","genericName":"Insulin lispro A","slug":"insulin-lispro-a","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro low mix","genericName":"Insulin lispro low mix","slug":"insulin-lispro-low-mix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro mix 25","genericName":"Insulin lispro mix 25","slug":"insulin-lispro-mix-25","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Intramuscular Glucagon","genericName":"Intramuscular Glucagon","slug":"intramuscular-glucagon","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"LY2189265","genericName":"LY2189265","slug":"ly2189265","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY2605541","genericName":"LY2605541","slug":"ly2605541","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"LY3537031","genericName":"LY3537031","slug":"ly3537031","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY3819253","genericName":"LY3819253","slug":"ly3819253","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY900003","genericName":"LY900003","slug":"ly900003","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY900014","genericName":"LY900014","slug":"ly900014","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Lispro Low Mix","genericName":"Lispro Low Mix","slug":"lispro-low-mix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Lispro Mid Mix","genericName":"Lispro Mid Mix","slug":"lispro-mid-mix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Lispro Mix 50/50","genericName":"Lispro Mix 50/50","slug":"lispro-mix-50-50","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Lispro mix 75/25","genericName":"Lispro mix 75/25","slug":"lispro-mix-75-25","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Nasal Glucagon (NG)","genericName":"Nasal Glucagon (NG)","slug":"nasal-glucagon-ng","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"Neutral protamine hagedorn insulin","genericName":"Neutral protamine hagedorn insulin","slug":"neutral-protamine-hagedorn-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"OAMs","genericName":"OAMs","slug":"oams","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Oral antihyperglycemics","genericName":"Oral antihyperglycemics","slug":"oral-antihyperglycemics","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Prandial Insulin Lispro","genericName":"Prandial Insulin Lispro","slug":"prandial-insulin-lispro","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Standard therapy for INCS","genericName":"Standard therapy for INCS","slug":"standard-therapy-for-incs","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Ultra-Rapid Lispro","genericName":"Ultra-Rapid Lispro","slug":"ultra-rapid-lispro","indication":"Treatment of diabetes mellitus","status":"phase_3"},{"name":"injected insulin","genericName":"injected insulin","slug":"injected-insulin","indication":"Type 1 diabetes","status":"phase_3"},{"name":"insulin lispro LM","genericName":"insulin lispro LM","slug":"insulin-lispro-lm","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"insulin lispro MM","genericName":"insulin lispro MM","slug":"insulin-lispro-mm","indication":"Type 1 diabetes mellitus","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":5300000000,"percentOfTotal":14.4,"drugCount":26,"colorKey":"immunology","drugs":[{"name":"Verzenio","genericName":"abemaciclib","slug":"abemaciclib","indication":"Hormone receptor positive malignant neoplasm of breast","status":"marketed","revenue":3700000000},{"name":"Cyramza","genericName":"RAMUCIRUMAB","slug":"ramucirumab","indication":"Adenocarcinoma of stomach","status":"marketed","revenue":900000000},{"name":"Retevmo","genericName":"SELPERCATINIB","slug":"selpercatinib","indication":"Advanced RET fusion-positive non-small cell lung cancer","status":"marketed","revenue":700000000},{"name":"Inluriyo","genericName":"IMLUNESTRANT","slug":"imlunestrant","indication":"ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","status":"marketed"},{"name":"ALIMTA plus Epirubicin","genericName":"ALIMTA plus Epirubicin","slug":"alimta-plus-epirubicin","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"Any platinum-based doublet chemotherapy","genericName":"Any platinum-based doublet chemotherapy","slug":"any-platinum-based-doublet-chemotherapy","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"BEC2 Vaccine","genericName":"BEC2 Vaccine","slug":"bec2-vaccine","indication":"Small cell lung cancer (SCLC)","status":"phase_3"},{"name":"Bevacizumab (Bev)","genericName":"Bevacizumab (Bev)","slug":"bevacizumab-bev","indication":"Metastatic colorectal cancer (in combination with chemotherapy)","status":"marketed"},{"name":"Docetaxel (Taxane)","genericName":"Docetaxel (Taxane)","slug":"docetaxel-taxane","indication":"Metastatic breast cancer","status":"phase_3"},{"name":"Eramin","genericName":"HISTAMINE","slug":"histamine","indication":"Acute myeloid leukemia, disease","status":"marketed"},{"name":"Erbitux (Cetuximab)","genericName":"Erbitux (Cetuximab)","slug":"erbitux-cetuximab","indication":"Metastatic colorectal cancer (KRAS wild-type)","status":"phase_3"},{"name":"Evista","genericName":"RALOXIFENE","slug":"raloxifene","indication":"Postmenopausal osteoporosis","status":"marketed"},{"name":"LOXO-305","genericName":"LOXO-305","slug":"loxo-305","indication":"Relapsed or refractory mantle cell lymphoma","status":"phase_2"},{"name":"LY3832479","genericName":"LY3832479","slug":"ly3832479","indication":"Metastatic non-small cell lung cancer","status":"phase_2"},{"name":"LY3838915","genericName":"LY3838915","slug":"ly3838915","indication":"Relapsed or refractory non-Hodgkin lymphoma","status":"phase_2"},{"name":"LY4065967","genericName":"LY4065967","slug":"ly4065967","indication":"FGFR-altered solid tumors (Phase 2 development)","status":"phase_2"},{"name":"Lartruvo","genericName":"OLARATUMAB","slug":"olaratumab","indication":"Sarcoma of soft tissue","status":"marketed"},{"name":"Metholone","genericName":"drostanolone propionate","slug":"drostanolone-propionate","indication":"Malignant neoplasm of breast","status":"marketed"},{"name":"Paclitaxel (Taxane)","genericName":"Paclitaxel (Taxane)","slug":"paclitaxel-taxane","indication":"Metastatic carcinoma of the ovary","status":"phase_3"},{"name":"Portrazza","genericName":"NECITUMUMAB","slug":"necitumumab","indication":"Non-small cell lung cancer","status":"marketed"},{"name":"Ramucirumab (IMC-1211B) DP","genericName":"Ramucirumab (IMC-1211B) DP","slug":"ramucirumab-imc-1211b-dp","indication":"Metastatic non-small cell lung cancer (in combination with docetaxel)","status":"phase_3"},{"name":"Ramucirumab DP (IMC-1121B)","genericName":"Ramucirumab DP (IMC-1121B)","slug":"ramucirumab-dp-imc-1121b","indication":"Non-small cell lung cancer, gastric cancer, and other solid tumors","status":"phase_3"},{"name":"Remternetug (IV)","genericName":"Remternetug (IV)","slug":"remternetug-iv","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Remternetug (SC)","genericName":"Remternetug (SC)","slug":"remternetug-sc","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Sofetabart Mipitecan","genericName":"Sofetabart Mipitecan","slug":"sofetabart-mipitecan","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"ramucirumab (IMC-1121B)","genericName":"ramucirumab (IMC-1121B)","slug":"ramucirumab-imc-1121b","indication":"Metastatic gastric cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":4700000000,"percentOfTotal":12.8,"drugCount":11,"colorKey":"cardiovascular","drugs":[{"name":"Taltz","genericName":"ixekizumab","slug":"ixekizumab","indication":"Ankylosing spondylitis","status":"marketed","revenue":2700000000},{"name":"Olumiant","genericName":"baricitinib","slug":"baricitinib","indication":"Alopecia areata","status":"marketed","revenue":1200000000},{"name":"Omvoh","genericName":"MIRIKIZUMAB","slug":"mirikizumab","indication":"Ulcerative Colitis","status":"marketed","revenue":800000000},{"name":"Ixekizumab Prefilled Syringe","genericName":"Ixekizumab Prefilled Syringe","slug":"ixekizumab-prefilled-syringe","indication":"Moderate to severe plaque psoriasis","status":"marketed"},{"name":"Commercially-available Aspirin","genericName":"Commercially-available Aspirin","slug":"commercially-available-aspirin","indication":"Acute myocardial infarction","status":"phase_3"},{"name":"Ixekizumab Auto-Injector","genericName":"Ixekizumab Auto-Injector","slug":"ixekizumab-auto-injector","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"OMVOH","genericName":"MIRIKIZUMAB-MRKZ","slug":"mirikizumab-mrkz","indication":"Moderately to severely active ulcerative colitis","status":"marketed"},{"name":"Sulfadiazine","genericName":"SULFADIAZINE","slug":"sulfadiazine","indication":"Burn Wound Infections","status":"marketed"},{"name":"Topical Corticosteroid (TCS)","genericName":"Topical Corticosteroid (TCS)","slug":"topical-corticosteroid-tcs","indication":"Eczema","status":"phase_3"},{"name":"Triamcinolone (Optional)","genericName":"Triamcinolone (Optional)","slug":"triamcinolone-optional","indication":"Inflammatory and allergic conditions (dermatitis, eczema, psoriasis)","status":"marketed"},{"name":"cDMARD","genericName":"cDMARD","slug":"cdmard","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":1800000000,"percentOfTotal":4.9,"drugCount":18,"colorKey":"neuroscience","drugs":[{"name":"Prozac","genericName":"fluoxetine","slug":"fluoxetine","indication":"Bipolar affective disorder, current episode depression","status":"marketed","revenue":1000000000},{"name":"Emgality","genericName":"GALCANEZUMAB","slug":"galcanezumab","indication":"Preventive treatment of migraine","status":"marketed","revenue":500000000},{"name":"Zyprexa","genericName":"olanzapine","slug":"olanzapine","indication":"Agitation associated with Bipolar Mania","status":"marketed","revenue":300000000},{"name":"Cymbalta","genericName":"duloxetine","slug":"duloxetine","indication":"Chronic Musculoskeletal Pain","status":"marketed"},{"name":"LY2216684","genericName":"LY2216684","slug":"ly2216684","indication":"Major depressive disorder","status":"phase_3"},{"name":"LY450139","genericName":"LY450139","slug":"ly450139","indication":"Alzheimer's disease (mild cognitive impairment and mild dementia stages)","status":"phase_3"},{"name":"Other standard therapy for ADHD","genericName":"Other standard therapy for ADHD","slug":"other-standard-therapy-for-adhd","indication":"Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"phase_3"},{"name":"Duloxetine (DLX)","genericName":"Duloxetine (DLX)","slug":"duloxetine-dlx","indication":"Major depressive disorder","status":"phase_3"},{"name":"Duloxetine Hydrochloride (HCI)","genericName":"Duloxetine Hydrochloride (HCI)","slug":"duloxetine-hydrochloride-hci","indication":"Major depressive disorder","status":"phase_3"},{"name":"Intramuscular Olanzapine Depot","genericName":"Intramuscular Olanzapine Depot","slug":"intramuscular-olanzapine-depot","indication":"Schizophrenia maintenance treatment","status":"phase_3"},{"name":"LY2216684 (edivoxetine)","genericName":"LY2216684 (edivoxetine)","slug":"ly2216684-edivoxetine","indication":"Attention-deficit/hyperactivity disorder (ADHD)","status":"phase_3"},{"name":"Oral Olanzapine","genericName":"Oral Olanzapine","slug":"oral-olanzapine","indication":"Schizophrenia","status":"marketed"},{"name":"Osmotic-release oral system methylphenidate","genericName":"Osmotic-release oral system methylphenidate","slug":"osmotic-release-oral-system-methylphenidate","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults","status":"marketed"},{"name":"Pagitane","genericName":"CYCRIMINE","slug":"cycrimine","indication":"Parkinson's disease","status":"marketed"},{"name":"Rapid Acting Intramuscular Olanzapine","genericName":"Rapid Acting Intramuscular Olanzapine","slug":"rapid-acting-intramuscular-olanzapine","indication":"Treatment of schizophrenia","status":"phase_3"},{"name":"Reyvow","genericName":"LASMIDITAN","slug":"lasmiditan","indication":"Migraine","status":"marketed"},{"name":"olanzapine pamoate depot","genericName":"olanzapine pamoate depot","slug":"olanzapine-pamoate-depot","indication":"Schizophrenia (maintenance treatment)","status":"phase_3"},{"name":"olanzapine therapy","genericName":"olanzapine therapy","slug":"olanzapine-therapy","indication":"Schizophrenia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":76,"colorKey":"infectious","drugs":[{"name":"Glargine","genericName":"Glargine","slug":"glargine","indication":"Other","status":"marketed"},{"name":"Strattera","genericName":"ATOMOXETINE","slug":"atomoxetine","indication":"Attention deficit hyperactivity disorder","status":"marketed"},{"name":"1121B","genericName":"1121B","slug":"1121b","indication":"Other","status":"phase_1"},{"name":"Decabid","genericName":"INDECAINIDE","slug":"indecainide","indication":"Other","status":"marketed"},{"name":"Glargine Basal-Bolus Therapy","genericName":"Glargine Basal-Bolus Therapy","slug":"glargine-basal-bolus-therapy","indication":"Other","status":"marketed"},{"name":"LY3819469","genericName":"LY3819469","slug":"ly3819469","indication":"Other","status":"phase_2"},{"name":"LY3848575","genericName":"LY3848575","slug":"ly3848575","indication":"Other","status":"phase_2"},{"name":"LY3962673","genericName":"LY3962673","slug":"ly3962673","indication":"Other","status":"phase_1"},{"name":"LY4100511","genericName":"LY4100511","slug":"ly4100511","indication":"Other","status":"phase_2"},{"name":"LY4175408","genericName":"LY4175408","slug":"ly4175408","indication":"Other","status":"phase_1"},{"name":"LY451395","genericName":"LY451395","slug":"ly451395","indication":"Other","status":"phase_2"},{"name":"Metocurine","genericName":"dimethyltubocurarinium","slug":"dimethyltubocurarinium","indication":"Muscle relaxation, function","status":"marketed"},{"name":"Placebo (PLA)","genericName":"Placebo (PLA)","slug":"placebo-pla","indication":"Control arm in randomized controlled trials across multiple therapeutic areas","status":"marketed"},{"name":"aldrenodate","genericName":"aldrenodate","slug":"aldrenodate","indication":"Other","status":"marketed"},{"name":"zuclopentixol","genericName":"zuclopentixol","slug":"zuclopentixol","indication":"Other","status":"marketed"},{"name":"Alfarol 1.0 µg","genericName":"Alfarol 1.0 µg","slug":"alfarol-1-0-g","indication":"Hypocalcemia and secondary hyperparathyroidism in chronic kidney disease","status":"marketed"},{"name":"Anastrozole, Exemestane, or Letrozole","genericName":"Anastrozole, Exemestane, or Letrozole","slug":"anastrozole-exemestane-or-letrozole","indication":"Other","status":"phase_1"},{"name":"Axiron","genericName":"Axiron","slug":"axiron","indication":"Other","status":"marketed"},{"name":"Background Chemotherapy","genericName":"Background Chemotherapy","slug":"background-chemotherapy","indication":"Other","status":"phase_2"},{"name":"Bortezomib IV","genericName":"Bortezomib IV","slug":"bortezomib-iv","indication":"Other","status":"phase_1"},{"name":"Brenipatide","genericName":"Brenipatide","slug":"brenipatide","indication":"Other","status":"phase_3"},{"name":"Dicurin Procaine","genericName":"MERETHOXYLLINE PROCAINE","slug":"merethoxylline-procaine","indication":"Other","status":"marketed"},{"name":"Digicor","genericName":"DIGITOXIN","slug":"digitoxin","indication":"Other","status":"marketed"},{"name":"Duloxetine hydrochloride - 60 mg","genericName":"Duloxetine hydrochloride - 60 mg","slug":"duloxetine-hydrochloride-60-mg","indication":"Other","status":"marketed"},{"name":"EBGLYSS","genericName":"LEBRIKIZUMAB-LBKZ","slug":"lebrikizumab-lbkz","indication":"Other","status":"marketed"},{"name":"Glinides","genericName":"Glinides","slug":"glinides","indication":"Other","status":"phase_3"},{"name":"Human insulin isophane suspension","genericName":"Human insulin isophane suspension","slug":"human-insulin-isophane-suspension","indication":"Other","status":"marketed"},{"name":"IMC-1121B","genericName":"IMC-1121B","slug":"imc-1121b","indication":"Other","status":"phase_2"},{"name":"IMC-18F1","genericName":"IMC-18F1","slug":"imc-18f1","indication":"Other","status":"phase_2"},{"name":"Insulin lispro B","genericName":"Insulin lispro B","slug":"insulin-lispro-b","indication":"Other","status":"phase_1"},{"name":"KISUNLA","genericName":"DONANEMAB-AZBT","slug":"donanemab-azbt","indication":"Other","status":"marketed"},{"name":"Kafocin","genericName":"cefaloglycin","slug":"cefaloglycin","indication":"Other","status":"marketed"},{"name":"Kappadione","genericName":"MENADIOL SODIUM DIPHOSPHATE","slug":"menadiol-sodium-diphosphate","indication":"Hemorrhage","status":"marketed"},{"name":"Kefadol","genericName":"CEFAMANDOLE NAFATE","slug":"cefamandole-nafate","indication":"Other","status":"marketed"},{"name":"LOXO-783","genericName":"LOXO-783","slug":"loxo-783","indication":"Other","status":"phase_1"},{"name":"LY2062430","genericName":"LY2062430","slug":"ly2062430","indication":"Huntington's disease","status":"phase_3"},{"name":"LY2189265 and Lifestyle Measures","genericName":"LY2189265 and Lifestyle Measures","slug":"ly2189265-and-lifestyle-measures","indication":"Other","status":"phase_2"},{"name":"LY2196044","genericName":"LY2196044","slug":"ly2196044","indication":"Other","status":"phase_2"},{"name":"LY2422347","genericName":"LY2422347","slug":"ly2422347","indication":"Other","status":"phase_2"},{"name":"LY2541546 - SC","genericName":"LY2541546 - SC","slug":"ly2541546-sc","indication":"Other","status":"phase_1"},{"name":"LY2584702 Reference Formulation","genericName":"LY2584702 Reference Formulation","slug":"ly2584702-reference-formulation","indication":"Other","status":"phase_1"},{"name":"LY2603618","genericName":"LY2603618","slug":"ly2603618","indication":"Other","status":"phase_2"},{"name":"LY2787106","genericName":"LY2787106","slug":"ly2787106","indication":"Other","status":"phase_1"},{"name":"LY3016859","genericName":"LY3016859","slug":"ly3016859","indication":"Other","status":"phase_2"},{"name":"LY3457263","genericName":"LY3457263","slug":"ly3457263","indication":"Other","status":"phase_2"},{"name":"LY3502970","genericName":"LY3502970","slug":"ly3502970","indication":"Other","status":"phase_2"},{"name":"LY3839840","genericName":"LY3839840","slug":"ly3839840","indication":"Other","status":"phase_1"},{"name":"LY3857210","genericName":"LY3857210","slug":"ly3857210","indication":"Other","status":"phase_2"},{"name":"LY4057996 IV","genericName":"LY4057996 IV","slug":"ly4057996-iv","indication":"Other","status":"phase_1"},{"name":"LY573636-sodium","genericName":"LY573636-sodium","slug":"ly573636-sodium","indication":"Other","status":"phase_2"},{"name":"Lispro","genericName":"Lispro","slug":"lispro","indication":"Other","status":"marketed"},{"name":"Lispro Prandial Insulin","genericName":"Lispro Prandial Insulin","slug":"lispro-prandial-insulin","indication":"Other","status":"phase_1"},{"name":"Menadion","genericName":"MENADIONE","slug":"menadione","indication":"Other","status":"marketed"},{"name":"Moxam","genericName":"latamoxef","slug":"latamoxef","indication":"Other","status":"marketed"},{"name":"PPAR alpha","genericName":"PPAR alpha","slug":"ppar-alpha","indication":"Other","status":"phase_2"},{"name":"Pemetrexed Phase 2","genericName":"Pemetrexed Phase 2","slug":"pemetrexed-phase-2","indication":"Other","status":"phase_2"},{"name":"Placebo (for Ramucirumab)","genericName":"Placebo (for Ramucirumab)","slug":"placebo-for-ramucirumab","indication":"Other","status":"phase_3"},{"name":"Placebo as Capsules","genericName":"Placebo as Capsules","slug":"placebo-as-capsules","indication":"Control arm in phase 3 clinical trials (specific indication unknown)","status":"phase_3"},{"name":"Placebo every 2 weeks","genericName":"Placebo every 2 weeks","slug":"placebo-every-2-weeks","indication":"Other","status":"phase_3"},{"name":"Placebo every 4 weeks","genericName":"Placebo every 4 weeks","slug":"placebo-every-4-weeks","indication":"Other","status":"phase_3"},{"name":"Placebo for Abemaciclib","genericName":"Placebo for Abemaciclib","slug":"placebo-for-abemaciclib","indication":"Control arm in phase 3 clinical trials of abemaciclib","status":"phase_3"},{"name":"Placebo-Oral","genericName":"Placebo-Oral","slug":"placebo-oral","indication":"Clinical trial control comparator (not a therapeutic indication)","status":"marketed"},{"name":"Platinol","genericName":"Platinol","slug":"platinol","indication":"Other","status":"phase_1"},{"name":"Raloxifene HCL","genericName":"Raloxifene HCL","slug":"raloxifene-hcl","indication":"Other","status":"marketed"},{"name":"Ramucirumab - SC","genericName":"Ramucirumab - SC","slug":"ramucirumab-sc","indication":"Other","status":"phase_1"},{"name":"Ramucirumab DP","genericName":"Ramucirumab DP","slug":"ramucirumab-dp","indication":"Other","status":"phase_2"},{"name":"Salmon Calcitonin","genericName":"Salmon Calcitonin","slug":"salmon-calcitonin","indication":"Paget's disease of bone","status":"marketed"},{"name":"Somatropin (rDNA origin)","genericName":"Somatropin (rDNA origin)","slug":"somatropin-rdna-origin","indication":"Growth hormone deficiency in children","status":"phase_3"},{"name":"Stimulants","genericName":"Stimulants","slug":"stimulants","indication":"Other","status":"phase_2"},{"name":"Tadalafil 5 mg","genericName":"Tadalafil 5 mg","slug":"tadalafil-5-mg","indication":"Other","status":"marketed"},{"name":"Vepugratinib","genericName":"Vepugratinib","slug":"vepugratinib","indication":"Other","status":"phase_3"},{"name":"[^13C4D3^15N]-baricitinib","genericName":"[^13C4D3^15N]-baricitinib","slug":"13c4d3-15n-baricitinib","indication":"Other","status":"phase_1"},{"name":"antiresorptives","genericName":"antiresorptives","slug":"antiresorptives","indication":"Other","status":"phase_2"},{"name":"placebo (tadalafil)","genericName":"placebo (tadalafil)","slug":"placebo-tadalafil","indication":"Erectile dysfunction","status":"phase_3"},{"name":"premeal insulin lispro mixtures","genericName":"premeal insulin lispro mixtures","slug":"premeal-insulin-lispro-mixtures","indication":"Other","status":"marketed"},{"name":"raloxifene HCI and alendronate Na","genericName":"raloxifene HCI and alendronate Na","slug":"raloxifene-hci-and-alendronate-na","indication":"Postmenopausal osteoporosis prevention and treatment","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"respiratory","drugs":[{"name":"Alpha1 Blocker","genericName":"Alpha1 Blocker","slug":"alpha1-blocker","indication":"Hypertension","status":"marketed"},{"name":"Cialis","genericName":"tadalafil","slug":"tadalafil","indication":"Benign prostatic hyperplasia","status":"marketed"},{"name":"ADP receptor inhibitors","genericName":"ADP receptor inhibitors","slug":"adp-receptor-inhibitors","indication":"Acute coronary syndrome","status":"phase_2"},{"name":"Dulaglutide Pen","genericName":"Dulaglutide Pen","slug":"dulaglutide-pen","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"ERA as specific PAH treatment","genericName":"ERA as specific PAH treatment","slug":"era-as-specific-pah-treatment","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"LY353381","genericName":"LY353381","slug":"ly353381","indication":"Osteoporosis prevention and treatment in postmenopausal women","status":"phase_3"},{"name":"Quinidine Gluconate","genericName":"QUINIDINE SULFATE","slug":"quinidine-sulfate","indication":"Atrial fibrillation","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"rare","drugs":[{"name":"Cinobac","genericName":"CINOXACIN","slug":"cinoxacin","indication":"Urinary tract infectious disease","status":"marketed"},{"name":"Cephalotin","genericName":"cefalotin","slug":"cefalotin","indication":"Bacterial infection due to Klebsiella pneumoniae","status":"marketed"},{"name":"Ly-Cov016","genericName":"ETESEVIMAB","slug":"etesevimab","indication":"COVID-19","status":"marketed"},{"name":"Ly-Cov555","genericName":"BAMLANIVIMAB","slug":"bamlanivimab","indication":"COVID-19","status":"discontinued"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"Ebglyss","genericName":"LEBRIKIZUMAB","slug":"lebrikizumab","indication":"Moderate-to-severe atopic dermatitis","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"Lebrikizumab Pen","genericName":"Lebrikizumab Pen","slug":"lebrikizumab-pen","indication":"Moderate-to-severe atopic dermatitis","status":"phase_3"}]}],"pipeline":[{"name":"Mounjaro","genericName":"TIRZEPATIDE","slug":"tirzepatide","phase":"marketed","mechanism":"Tirzepatide is a dual GIP and GLP-1 receptor agonist with C20 fatty diacid for albumin binding.","indications":["Diabetes mellitus type 2"],"catalyst":""},{"name":"Trulicity","genericName":"DULAGLUTIDE","slug":"dulaglutide","phase":"marketed","mechanism":"Dulaglutide activates GLP-1 receptors, increasing insulin release and decreasing glucagon secretion and gastric emptying.","indications":["Diabetes mellitus type 2"],"catalyst":""},{"name":"Verzenio","genericName":"abemaciclib","slug":"abemaciclib","phase":"marketed","mechanism":"Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression.","indications":["Hormone receptor positive malignant neoplasm of breast","Human epidermal growth factor 2 negative carcinoma of breast"],"catalyst":""},{"name":"Taltz","genericName":"ixekizumab","slug":"ixekizumab","phase":"marketed","mechanism":"Humanized IgG4 monoclonal antibody that selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor.","indications":["Ankylosing spondylitis","Erythrodermic psoriasis","Non-radiographic axial spondyloarthritis","Plaque psoriasis","Psoriatic arthritis"],"catalyst":""},{"name":"Humalog","genericName":"INSULIN LISPRO","slug":"insulin-lispro","phase":"marketed","mechanism":"Humalog works by mimicking the natural hormone insulin to help cells absorb glucose from the bloodstream.","indications":["Diabetes mellitus type 1","Diabetes mellitus type 2"],"catalyst":""},{"name":"Olumiant","genericName":"baricitinib","slug":"baricitinib","phase":"marketed","mechanism":"Tyrosine-protein kinase JAK2","indications":["Alopecia areata","Atopic dermatitis","Pneumonia caused by Severe acute respiratory syndrome coronavirus 2","Rheumatoid arthritis"],"catalyst":""},{"name":"Prozac","genericName":"fluoxetine","slug":"fluoxetine","phase":"marketed","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown.","indications":["Bipolar affective disorder, current episode depression","Bulimia nervosa","Depressive disorder","Major depressive disorder","Obsessive-compulsive disorder"],"catalyst":""},{"name":"Cyramza","genericName":"RAMUCIRUMAB","slug":"ramucirumab","phase":"marketed","mechanism":"Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread.","indications":["Adenocarcinoma of stomach","Liver cell carcinoma","Malignant neoplasm of colon and/or rectum","Malignant tumor of stomach","Non-small cell lung cancer"],"catalyst":""},{"name":"Omvoh","genericName":"MIRIKIZUMAB","slug":"mirikizumab","phase":"marketed","mechanism":"MIRIKIZUMAB blocks the activity of Interleukin-23, a protein involved in inflammation.","indications":["Ulcerative Colitis","Crohn's Disease"],"catalyst":""},{"name":"Retevmo","genericName":"SELPERCATINIB","slug":"selpercatinib","phase":"marketed","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells.","indications":["Advanced RET fusion-positive non-small cell lung cancer","Advanced RET fusion-positive thyroid cancer","Medullary thyroid carcinoma","Metastasis from malignant tumor of thyroid","Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"Emgality","genericName":"GALCANEZUMAB","slug":"galcanezumab","phase":"marketed","mechanism":"Emgality works by binding to calcitonin gene-related peptide 1 (CGRP1), preventing it from triggering migraine attacks.","indications":["Preventive treatment of migraine","Treatment of episodic cluster headache"],"catalyst":""},{"name":"Zyprexa","genericName":"olanzapine","slug":"olanzapine","phase":"marketed","mechanism":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","indications":["Agitation associated with Bipolar Mania","Agitation associated with Schizophrenia","Bipolar affective disorder, current episode depression","Bipolar affective disorder, current episode manic","Bipolar disorder in remission"],"catalyst":""},{"name":"Cymbalta","genericName":"duloxetine","slug":"duloxetine","phase":"marketed","mechanism":"Potentiates serotonergic and noradrenergic activity in the CNS through unknown exact mechanisms.","indications":["Chronic Musculoskeletal Pain","Diabetic peripheral neuropathy","Female stress incontinence","Fibromyalgia","Generalized anxiety disorder"],"catalyst":""},{"name":"Humulin","genericName":"insulin","slug":"insulin","phase":"marketed","mechanism":"Humulin works by binding to insulin receptors on cells, triggering a cascade of signals that lower blood glucose levels.","indications":["Diabetes mellitus type 1","Diabetes mellitus type 2"],"catalyst":""},{"name":"Glargine","genericName":"Glargine","slug":"glargine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Inluriyo","genericName":"IMLUNESTRANT","slug":"imlunestrant","phase":"marketed","mechanism":"Inluriyo works by blocking estrogen receptors on cancer cells, preventing them from growing and spreading.","indications":["ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy"],"catalyst":""},{"name":"Strattera","genericName":"ATOMOXETINE","slug":"atomoxetine","phase":"marketed","mechanism":"Strattera works by blocking the reabsorption of norepinephrine in the brain, allowing more of this neurotransmitter to be available for use.","indications":["Attention deficit hyperactivity disorder"],"catalyst":""},{"name":"1121B","genericName":"1121B","slug":"1121b","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Alpha1 Blocker","genericName":"Alpha1 Blocker","slug":"alpha1-blocker","phase":"marketed","mechanism":"Alpha-1 blockers inhibit alpha-1 adrenergic receptors on vascular smooth muscle and the prostate, causing vasodilation and reduced urinary obstruction.","indications":["Hypertension","Benign prostatic hyperplasia with lower urinary tract symptoms"],"catalyst":""},{"name":"Cialis","genericName":"tadalafil","slug":"tadalafil","phase":"marketed","mechanism":"Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2","indications":["Benign prostatic hyperplasia","Impotence","Pulmonary hypertension"],"catalyst":""},{"name":"Cinobac","genericName":"CINOXACIN","slug":"cinoxacin","phase":"marketed","mechanism":"Carbonic anhydrase 2","indications":["Urinary tract infectious disease"],"catalyst":""},{"name":"Decabid","genericName":"INDECAINIDE","slug":"indecainide","phase":"marketed","mechanism":"Sodium channel protein type 5 subunit alpha","indications":[],"catalyst":""},{"name":"Dymelor","genericName":"ACETOHEXAMIDE","slug":"acetohexamide","phase":"marketed","mechanism":"Sulfonylurea receptor 1, Kir6.2","indications":["Diabetes mellitus type 2"],"catalyst":""},{"name":"Glargine Basal-Bolus Therapy","genericName":"Glargine Basal-Bolus Therapy","slug":"glargine-basal-bolus-therapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glucagon Hydrochloride Solution","genericName":"Glucagon Hydrochloride Solution","slug":"glucagon-hydrochloride-solution","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes mellitus","Diagnostic aid in radiologic examination of the gastrointestinal tract"],"catalyst":""},{"name":"Glucagon IM","genericName":"Glucagon IM","slug":"glucagon-im","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Glucagon Nasal Powder","genericName":"Glucagon Nasal Powder","slug":"glucagon-nasal-powder","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Human Insulin Inhalation Powder","genericName":"Human Insulin Inhalation Powder","slug":"human-insulin-inhalation-powder","phase":"phase_3","mechanism":"Human insulin delivered via inhalation powder replaces or supplements endogenous insulin to regulate blood glucose by promoting glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Human Insulin Mix 50:50","genericName":"Human Insulin Mix 50:50","slug":"human-insulin-mix-50-50","phase":"phase_3","mechanism":"Human Insulin Mix 50:50 replaces deficient endogenous insulin by binding to insulin receptors on target cells to promote glucose uptake and utilization.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Huminsulin Regular","genericName":"Huminsulin Regular","slug":"huminsulin-regular","phase":"marketed","mechanism":"Huminsulin Regular is a recombinant human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro (U100)","genericName":"Insulin Lispro (U100)","slug":"insulin-lispro-u100","phase":"phase_3","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for blood sugar control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Mix50","genericName":"Insulin Lispro Mix50","slug":"insulin-lispro-mix50","phase":"marketed","mechanism":"Insulin Lispro Mix50 is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro-aabc","genericName":"Insulin Lispro-aabc","slug":"insulin-lispro-aabc","phase":"marketed","mechanism":"Insulin Lispro-aabc is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro 2 day reservoir in-use","genericName":"Insulin lispro 2 day reservoir in-use","slug":"insulin-lispro-2-day-reservoir-in-use","phase":"phase_3","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Ixekizumab Prefilled Syringe","genericName":"Ixekizumab Prefilled Syringe","slug":"ixekizumab-prefilled-syringe","phase":"marketed","mechanism":"Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"catalyst":""},{"name":"LY2216684","genericName":"LY2216684","slug":"ly2216684","phase":"phase_3","mechanism":"LY2216684 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.","indications":["Major depressive disorder","Circadian rhythm sleep disorders"],"catalyst":""},{"name":"LY2963016","genericName":"LY2963016","slug":"ly2963016","phase":"phase_3","mechanism":"LY2963016 is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY3537982","genericName":"LY3537982","slug":"ly3537982","phase":"phase_3","mechanism":"LY3537982 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY3650150","genericName":"LY3650150","slug":"ly3650150","phase":"phase_3","mechanism":"LY3650150 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY3819469","genericName":"LY3819469","slug":"ly3819469","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3848575","genericName":"LY3848575","slug":"ly3848575","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3962673","genericName":"LY3962673","slug":"ly3962673","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4100511","genericName":"LY4100511","slug":"ly4100511","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4175408","genericName":"LY4175408","slug":"ly4175408","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY450139","genericName":"LY450139","slug":"ly450139","phase":"phase_3","mechanism":"LY450139 is a gamma-secretase inhibitor that reduces the production of amyloid-beta by blocking the cleavage of amyloid precursor protein.","indications":["Alzheimer's disease (mild cognitive impairment and mild dementia stages)"],"catalyst":""},{"name":"LY451395","genericName":"LY451395","slug":"ly451395","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lispro Mixture Therapy","genericName":"Lispro Mixture Therapy","slug":"lispro-mixture-therapy","phase":"marketed","mechanism":"Lispro Mixture is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Metocurine","genericName":"dimethyltubocurarinium","slug":"dimethyltubocurarinium","phase":"marketed","mechanism":"Acetylcholine receptor","indications":["Muscle relaxation, function"],"catalyst":""},{"name":"Other standard therapy for ADHD","genericName":"Other standard therapy for ADHD","slug":"other-standard-therapy-for-adhd","phase":"phase_3","mechanism":"This represents a standard ADHD therapy from Eli Lilly, likely a stimulant or non-stimulant that increases dopamine and/or norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.","indications":["Attention-Deficit/Hyperactivity Disorder (ADHD)"],"catalyst":""},{"name":"Placebo (PLA)","genericName":"Placebo (PLA)","slug":"placebo-pla","phase":"marketed","mechanism":"Placebo produces therapeutic effects through the patient's expectation and belief in treatment, activating endogenous healing mechanisms independent of pharmacological action.","indications":["Control arm in randomized controlled trials across multiple therapeutic areas"],"catalyst":""},{"name":"aldrenodate","genericName":"aldrenodate","slug":"aldrenodate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"zuclopentixol","genericName":"zuclopentixol","slug":"zuclopentixol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ADP receptor inhibitors","genericName":"ADP receptor inhibitors","slug":"adp-receptor-inhibitors","phase":"phase_2","mechanism":"ADP receptor inhibitors block the action of ADP on its receptor, preventing platelet activation and aggregation.","indications":["Acute coronary syndrome","Myocardial infarction"],"catalyst":""},{"name":"ALIMTA plus Epirubicin","genericName":"ALIMTA plus Epirubicin","slug":"alimta-plus-epirubicin","phase":"phase_1","mechanism":"Topoisomerase I inhibitor","indications":["Non-small cell lung cancer","Mesothelioma"],"catalyst":""},{"name":"AM0010","genericName":"AM0010","slug":"am0010","phase":"phase_2","mechanism":"AM0010 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Alfarol 1.0 µg","genericName":"Alfarol 1.0 µg","slug":"alfarol-1-0-g","phase":"marketed","mechanism":"Alfarol is an active vitamin D analog that binds to the vitamin D receptor to regulate calcium and phosphate homeostasis.","indications":["Hypocalcemia and secondary hyperparathyroidism in chronic kidney disease","Hypoparathyroidism","Vitamin D-dependent rickets","Osteoporosis"],"catalyst":""},{"name":"Analog or Human Insulin","genericName":"Analog or Human Insulin","slug":"analog-or-human-insulin","phase":"phase_2","mechanism":"Human insulin analogs mimic the action of the body's natural insulin, helping to lower blood sugar levels.","indications":["Type 1 diabetes","Type 2 diabetes"],"catalyst":""},{"name":"Anastrozole, Exemestane, or Letrozole","genericName":"Anastrozole, Exemestane, or Letrozole","slug":"anastrozole-exemestane-or-letrozole","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Any platinum-based doublet chemotherapy","genericName":"Any platinum-based doublet chemotherapy","slug":"any-platinum-based-doublet-chemotherapy","phase":"phase_2","mechanism":"Platinum-based doublet chemotherapy works by interfering with DNA replication in cancer cells, ultimately leading to cell death.","indications":["Non-small cell lung cancer","Small cell lung cancer","Ovarian cancer","Bladder cancer","Head and neck cancer"],"catalyst":""},{"name":"Axiron","genericName":"Axiron","slug":"axiron","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BEC2 Vaccine","genericName":"BEC2 Vaccine","slug":"bec2-vaccine","phase":"phase_3","mechanism":"BEC2 is a therapeutic cancer vaccine that targets the GD3 ganglioside antigen expressed on tumor cells to stimulate an immune response against cancer.","indications":["Small cell lung cancer (SCLC)","Melanoma"],"catalyst":""},{"name":"Background Chemotherapy","genericName":"Background Chemotherapy","slug":"background-chemotherapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Basal Insulin Analog","genericName":"Basal Insulin Analog","slug":"basal-insulin-analog","phase":"marketed","mechanism":"Basal insulin analogs mimic the body's natural background insulin secretion by binding to insulin receptors and promoting glucose uptake into cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Bevacizumab (Bev)","genericName":"Bevacizumab (Bev)","slug":"bevacizumab-bev","phase":"marketed","mechanism":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","indications":["Metastatic colorectal cancer (in combination with chemotherapy)","Metastatic non-small cell lung cancer (in combination with chemotherapy)","Metastatic breast cancer (in combination with chemotherapy)","Glioblastoma (recurrent)","Metastatic renal cell carcinoma (in combination with interferon-alpha)"],"catalyst":""},{"name":"Biguanide (BG)","genericName":"Biguanide (BG)","slug":"biguanide-bg","phase":"phase_3","mechanism":"Biguanides reduce hepatic glucose production and improve insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Biguanides (BG)","genericName":"Biguanides (BG)","slug":"biguanides-bg","phase":"phase_3","mechanism":"Biguanides reduce hepatic glucose production and improve insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial glycerol-3-phosphate dehydrogenase.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Bortezomib IV","genericName":"Bortezomib IV","slug":"bortezomib-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brenipatide","genericName":"Brenipatide","slug":"brenipatide","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cephalotin","genericName":"cefalotin","slug":"cefalotin","phase":"marketed","mechanism":"Solute carrier family 22 member 8","indications":["Bacterial infection due to Klebsiella pneumoniae","Bacterial septicemia","Female genital tract infection","Genitourinary Tract Infections","Haemophilus influenzae pneumonia"],"catalyst":""},{"name":"Commercially-available Aspirin","genericName":"Commercially-available Aspirin","slug":"commercially-available-aspirin","phase":"phase_3","mechanism":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.","indications":["Acute myocardial infarction","Ischemic stroke prevention","Transient ischemic attack (TIA) prevention","Coronary artery disease","Mild to moderate pain"],"catalyst":""},{"name":"Dicurin Procaine","genericName":"MERETHOXYLLINE PROCAINE","slug":"merethoxylline-procaine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Digicor","genericName":"DIGITOXIN","slug":"digitoxin","phase":"marketed","mechanism":"Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1","indications":[],"catalyst":""},{"name":"Docetaxel (Taxane)","genericName":"Docetaxel (Taxane)","slug":"docetaxel-taxane","phase":"phase_3","mechanism":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic breast cancer","Non-small cell lung cancer","Prostate cancer","Gastric cancer","Head and neck cancer"],"catalyst":""},{"name":"Dulaglutide Pen","genericName":"Dulaglutide Pen","slug":"dulaglutide-pen","phase":"marketed","mechanism":"Dulaglutide activates GLP-1 receptors on pancreatic beta cells to increase insulin secretion and suppress glucagon in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus","Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease"],"catalyst":""},{"name":"Duloxetine (DLX)","genericName":"Duloxetine (DLX)","slug":"duloxetine-dlx","phase":"phase_3","mechanism":"Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","indications":["Major depressive disorder","Generalized anxiety disorder","Diabetic peripheral neuropathic pain","Fibromyalgia","Chronic musculoskeletal pain"],"catalyst":""},{"name":"Duloxetine Hydrochloride (HCI)","genericName":"Duloxetine Hydrochloride (HCI)","slug":"duloxetine-hydrochloride-hci","phase":"phase_3","mechanism":"Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","indications":["Major depressive disorder","Generalized anxiety disorder","Diabetic peripheral neuropathic pain","Fibromyalgia","Chronic musculoskeletal pain"],"catalyst":""},{"name":"Duloxetine hydrochloride - 60 mg","genericName":"Duloxetine hydrochloride - 60 mg","slug":"duloxetine-hydrochloride-60-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EBGLYSS","genericName":"LEBRIKIZUMAB-LBKZ","slug":"lebrikizumab-lbkz","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"ERA as specific PAH treatment","genericName":"ERA as specific PAH treatment","slug":"era-as-specific-pah-treatment","phase":"phase_3","mechanism":"Endothelin receptor antagonists (ERAs) block endothelin-1 signaling in pulmonary vasculature to reduce vasoconstriction and improve hemodynamics in pulmonary arterial hypertension.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"Ebglyss","genericName":"LEBRIKIZUMAB","slug":"lebrikizumab","phase":"marketed","mechanism":"Ebglyss works by binding to interleukin-13, a protein that promotes inflammation in the skin.","indications":["Moderate-to-severe atopic dermatitis"],"catalyst":""},{"name":"Eramin","genericName":"HISTAMINE","slug":"histamine","phase":"marketed","mechanism":"Histamine H3 receptor","indications":["Acute myeloid leukemia, disease","Hyposensitization to allergens","Osteoarthritis"],"catalyst":""},{"name":"Erbitux (Cetuximab)","genericName":"Erbitux (Cetuximab)","slug":"erbitux-cetuximab","phase":"phase_3","mechanism":"Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing tumor growth and survival signals.","indications":["Metastatic colorectal cancer (KRAS wild-type)","Squamous cell carcinoma of the head and neck","Non-small cell lung cancer"],"catalyst":""},{"name":"Evista","genericName":"RALOXIFENE","slug":"raloxifene","phase":"marketed","mechanism":"Raloxifene binds to estrogen receptors, acting as an agonist in bone and an antagonist in uterine and breast tissues.","indications":["Postmenopausal osteoporosis","Prevention of Breast Carcinoma"],"catalyst":""},{"name":"Exenatide once weekly (QW)","genericName":"Exenatide once weekly (QW)","slug":"exenatide-once-weekly-qw","phase":"marketed","mechanism":"Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Exenatide twice daily (BID)","genericName":"Exenatide twice daily (BID)","slug":"exenatide-twice-daily-bid","phase":"marketed","mechanism":"Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Glinides","genericName":"Glinides","slug":"glinides","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Humalog Mix 50","genericName":"Humalog Mix 50","slug":"humalog-mix-50","phase":"phase_3","mechanism":"Humalog Mix 50 is a combination insulin therapy that provides both rapid-acting and intermediate-acting insulin to control blood glucose levels in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Human Regular U-500 Insulin","genericName":"Human Regular U-500 Insulin","slug":"human-regular-u-500-insulin","phase":"marketed","mechanism":"Human Regular U-500 Insulin is a concentrated insulin formulation that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus (particularly in insulin-resistant patients requiring high doses)"],"catalyst":""},{"name":"Human insulin 30/70","genericName":"Human insulin 30/70","slug":"human-insulin-30-70","phase":"marketed","mechanism":"Human insulin 30/70 is a fixed-ratio combination of 30% short-acting insulin and 70% intermediate-acting insulin that replaces endogenous insulin to regulate blood glucose by promoting cellular glucose uptake and storage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Human insulin isophane suspension","genericName":"Human insulin isophane suspension","slug":"human-insulin-isophane-suspension","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IMC-1121B","genericName":"IMC-1121B","slug":"imc-1121b","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IMC-18F1","genericName":"IMC-18F1","slug":"imc-18f1","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Injectable insulin","genericName":"Injectable insulin","slug":"injectable-insulin","phase":"marketed","mechanism":"Injectable insulin replaces or supplements the body's own insulin to regulate blood glucose by facilitating cellular glucose uptake and storage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus (when oral agents are insufficient)"],"catalyst":""},{"name":"Insulin Analog Mid Mixture","genericName":"Insulin Analog Mid Mixture","slug":"insulin-analog-mid-mixture","phase":"marketed","mechanism":"This insulin analog mixture mimics natural insulin by binding to insulin receptors to promote glucose uptake and utilization in cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Aspart 6 Day (6D)","genericName":"Insulin Aspart 6 Day (6D)","slug":"insulin-aspart-6-day-6d","phase":"phase_3","mechanism":"Insulin Aspart 6 Day is a long-acting basal insulin analog designed to provide extended glucose control with a 6-day duration of action.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Biphasic Aspart 30/70","genericName":"Insulin Biphasic Aspart 30/70","slug":"insulin-biphasic-aspart-30-70","phase":"marketed","mechanism":"Insulin biphasic aspart 30/70 is a premixed insulin combining 30% rapid-acting aspart and 70% intermediate-acting aspart to provide both immediate and sustained blood glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro 6 Day (6D)","genericName":"Insulin Lispro 6 Day (6D)","slug":"insulin-lispro-6-day-6d","phase":"phase_3","mechanism":"Insulin Lispro 6 Day is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Mix25","genericName":"Insulin Lispro Mix25","slug":"insulin-lispro-mix25","phase":"marketed","mechanism":"Insulin Lispro Mix25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Premix","genericName":"Insulin Lispro Premix","slug":"insulin-lispro-premix","phase":"marketed","mechanism":"Insulin lispro premix is a fixed combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics physiologic insulin secretion by providing both mealtime and basal glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Protamine Suspension","genericName":"Insulin Lispro Protamine Suspension","slug":"insulin-lispro-protamine-suspension","phase":"marketed","mechanism":"Insulin lispro protamine suspension is a long-acting basal insulin that binds to insulin receptors on muscle and fat cells to promote glucose uptake and storage, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro low mixture","genericName":"Insulin Lispro low mixture","slug":"insulin-lispro-low-mixture","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin aspart 6 day reservoir in-use","genericName":"Insulin aspart 6 day reservoir in-use","slug":"insulin-aspart-6-day-reservoir-in-use","phase":"phase_3","mechanism":"Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro (Humalog)","genericName":"Insulin lispro (Humalog)","slug":"insulin-lispro-humalog","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro 6 day reservoir in-use","genericName":"Insulin lispro 6 day reservoir in-use","slug":"insulin-lispro-6-day-reservoir-in-use","phase":"phase_3","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro A","genericName":"Insulin lispro A","slug":"insulin-lispro-a","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for blood sugar control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro B","genericName":"Insulin lispro B","slug":"insulin-lispro-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Insulin lispro low mix","genericName":"Insulin lispro low mix","slug":"insulin-lispro-low-mix","phase":"marketed","mechanism":"Insulin lispro low mix is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiological insulin secretion by providing both mealtime and basal insulin coverage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro mix 25","genericName":"Insulin lispro mix 25","slug":"insulin-lispro-mix-25","phase":"phase_3","mechanism":"Insulin lispro mix 25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Intramuscular Glucagon","genericName":"Intramuscular Glucagon","slug":"intramuscular-glucagon","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Intramuscular Olanzapine Depot","genericName":"Intramuscular Olanzapine Depot","slug":"intramuscular-olanzapine-depot","phase":"phase_3","mechanism":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia maintenance treatment","Bipolar I disorder maintenance treatment"],"catalyst":""},{"name":"Ixekizumab Auto-Injector","genericName":"Ixekizumab Auto-Injector","slug":"ixekizumab-auto-injector","phase":"phase_3","mechanism":"Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"catalyst":""},{"name":"KISUNLA","genericName":"DONANEMAB-AZBT","slug":"donanemab-azbt","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Kafocin","genericName":"cefaloglycin","slug":"cefaloglycin","phase":"marketed","mechanism":"Bacterial penicillin-binding protein","indications":[],"catalyst":""},{"name":"Kappadione","genericName":"MENADIOL SODIUM DIPHOSPHATE","slug":"menadiol-sodium-diphosphate","phase":"marketed","mechanism":"Small molecule","indications":["Hemorrhage","Obstructive hyperbilirubinemia"],"catalyst":""},{"name":"Kefadol","genericName":"CEFAMANDOLE NAFATE","slug":"cefamandole-nafate","phase":"marketed","mechanism":"Kefadol works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","indications":[],"catalyst":""},{"name":"LOXO-305","genericName":"LOXO-305","slug":"loxo-305","phase":"phase_2","mechanism":"Selective Bruton's tyrosine kinase (BTK) inhibitor","indications":["Relapsed or refractory mantle cell lymphoma","Relapsed or refractory marginal zone lymphoma"],"catalyst":""},{"name":"LOXO-783","genericName":"LOXO-783","slug":"loxo-783","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2062430","genericName":"LY2062430","slug":"ly2062430","phase":"phase_3","mechanism":"LY2062430 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain.","indications":["Huntington's disease"],"catalyst":""},{"name":"LY2189265","genericName":"LY2189265","slug":"ly2189265","phase":"phase_3","mechanism":"LY2189265 is a long-acting GLP-1 receptor agonist that mimics glucagon-like peptide-1 to improve blood glucose control by stimulating insulin secretion and reducing glucagon release.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY2189265 and Lifestyle Measures","genericName":"LY2189265 and Lifestyle Measures","slug":"ly2189265-and-lifestyle-measures","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2196044","genericName":"LY2196044","slug":"ly2196044","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2216684 (edivoxetine)","genericName":"LY2216684 (edivoxetine)","slug":"ly2216684-edivoxetine","phase":"phase_3","mechanism":"LY2216684 (edivoxetine) is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system.","indications":["Attention-deficit/hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"LY2422347","genericName":"LY2422347","slug":"ly2422347","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2541546 - SC","genericName":"LY2541546 - SC","slug":"ly2541546-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2584702 Reference Formulation","genericName":"LY2584702 Reference Formulation","slug":"ly2584702-reference-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2603618","genericName":"LY2603618","slug":"ly2603618","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2605541","genericName":"LY2605541","slug":"ly2605541","phase":"phase_3","mechanism":"LY2605541 is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose levels in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY2787106","genericName":"LY2787106","slug":"ly2787106","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3016859","genericName":"LY3016859","slug":"ly3016859","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3457263","genericName":"LY3457263","slug":"ly3457263","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3502970","genericName":"LY3502970","slug":"ly3502970","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY353381","genericName":"LY353381","slug":"ly353381","phase":"phase_3","mechanism":"LY353381 is a selective estrogen receptor modulator (SERM) that acts as a partial agonist at estrogen receptors to provide bone-protective and cardiovascular benefits without stimulating breast or endometrial tissue.","indications":["Osteoporosis prevention and treatment in postmenopausal women","Cardiovascular risk reduction in postmenopausal women"],"catalyst":""},{"name":"LY3537031","genericName":"LY3537031","slug":"ly3537031","phase":"phase_3","mechanism":"LY3537031 is a GLP-1 and GIP receptor dual agonist that activates both incretin pathways to improve glucose control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY3819253","genericName":"LY3819253","slug":"ly3819253","phase":"phase_3","mechanism":"LY3819253 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY3832479","genericName":"LY3832479","slug":"ly3832479","phase":"phase_2","mechanism":"LY3832479 is a small molecule that acts as a selective and potent inhibitor of the cyclin-dependent kinase 9 (CDK9).","indications":["Metastatic non-small cell lung cancer","Metastatic triple-negative breast cancer"],"catalyst":""},{"name":"LY3838915","genericName":"LY3838915","slug":"ly3838915","phase":"phase_2","mechanism":"LY3838915 is a small molecule that targets the CDK9 protein.","indications":["Relapsed or refractory non-Hodgkin lymphoma"],"catalyst":""},{"name":"LY3839840","genericName":"LY3839840","slug":"ly3839840","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3857210","genericName":"LY3857210","slug":"ly3857210","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4057996 IV","genericName":"LY4057996 IV","slug":"ly4057996-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4065967","genericName":"LY4065967","slug":"ly4065967","phase":"phase_2","mechanism":"LY4065967 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.","indications":["FGFR-altered solid tumors (Phase 2 development)"],"catalyst":""},{"name":"LY573636-sodium","genericName":"LY573636-sodium","slug":"ly573636-sodium","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY900003","genericName":"LY900003","slug":"ly900003","phase":"phase_3","mechanism":"LY900003 is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY900014","genericName":"LY900014","slug":"ly900014","phase":"phase_3","mechanism":"LY900014 is a rapid-acting insulin lispro formulation that mimics endogenous insulin by binding to insulin receptors to facilitate glucose uptake and metabolism.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Lartruvo","genericName":"OLARATUMAB","slug":"olaratumab","phase":"marketed","mechanism":"Platelet-derived growth factor receptor alpha","indications":["Sarcoma of soft tissue"],"catalyst":""},{"name":"Lebrikizumab Pen","genericName":"Lebrikizumab Pen","slug":"lebrikizumab-pen","phase":"phase_3","mechanism":"Lebrikizumab is a monoclonal antibody that blocks interleukin-4 receptor alpha (IL-4Rα), inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammation.","indications":["Moderate-to-severe atopic dermatitis","Uncontrolled asthma with type 2 inflammation"],"catalyst":""},{"name":"Lispro","genericName":"Lispro","slug":"lispro","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lispro Low Mix","genericName":"Lispro Low Mix","slug":"lispro-low-mix","phase":"marketed","mechanism":"Lispro Low Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Lispro Mid Mix","genericName":"Lispro Mid Mix","slug":"lispro-mid-mix","phase":"marketed","mechanism":"Lispro Mid Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics the body's natural insulin secretion pattern by providing both immediate and sustained glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Lispro Mix 50/50","genericName":"Lispro Mix 50/50","slug":"lispro-mix-50-50","phase":"marketed","mechanism":"Lispro Mix 50/50 is a combination insulin that provides both rapid-acting and intermediate-acting insulin to control blood glucose in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Lispro Prandial Insulin","genericName":"Lispro Prandial Insulin","slug":"lispro-prandial-insulin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lispro mix 75/25","genericName":"Lispro mix 75/25","slug":"lispro-mix-75-25","phase":"marketed","mechanism":"Lispro mix 75/25 is a combination insulin that provides rapid-acting insulin coverage for mealtime glucose spikes plus intermediate-acting basal insulin for baseline glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Ly-Cov016","genericName":"ETESEVIMAB","slug":"etesevimab","phase":"marketed","mechanism":"Monoclonal antibody","indications":["COVID-19"],"catalyst":""},{"name":"Ly-Cov555","genericName":"BAMLANIVIMAB","slug":"bamlanivimab","phase":"discontinued","mechanism":"Ly-Cov555 works by binding to the SARS-CoV-2 virus and preventing it from entering host cells.","indications":["COVID-19"],"catalyst":""},{"name":"Menadion","genericName":"MENADIONE","slug":"menadione","phase":"marketed","mechanism":"Aldehyde oxidase, Alpha-synuclein, Dual specificity phosphatase Cdc25A","indications":[],"catalyst":""},{"name":"Metholone","genericName":"drostanolone propionate","slug":"drostanolone-propionate","phase":"marketed","mechanism":"Androgen receptor","indications":["Malignant neoplasm of breast"],"catalyst":""},{"name":"Moxam","genericName":"latamoxef","slug":"latamoxef","phase":"marketed","mechanism":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","indications":[],"catalyst":""},{"name":"Nasal Glucagon (NG)","genericName":"Nasal Glucagon (NG)","slug":"nasal-glucagon-ng","phase":"phase_3","mechanism":"Nasal glucagon activates glucagon receptors to rapidly increase blood glucose levels in hypoglycemic emergencies.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Neutral protamine hagedorn insulin","genericName":"Neutral protamine hagedorn insulin","slug":"neutral-protamine-hagedorn-insulin","phase":"marketed","mechanism":"NPH insulin is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"OAMs","genericName":"OAMs","slug":"oams","phase":"phase_3","mechanism":"OAMs are oral antidiabetic agents that work through multiple mechanisms to improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"OMVOH","genericName":"MIRIKIZUMAB-MRKZ","slug":"mirikizumab-mrkz","phase":"marketed","mechanism":"Interleukin-23 subunit alpha","indications":["Moderately to severely active ulcerative colitis"],"catalyst":""},{"name":"Oral Olanzapine","genericName":"Oral Olanzapine","slug":"oral-olanzapine","phase":"marketed","mechanism":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Agitation associated with schizophrenia or bipolar disorder","Adjunctive treatment of major depressive disorder"],"catalyst":""},{"name":"Oral antihyperglycemics","genericName":"Oral antihyperglycemics","slug":"oral-antihyperglycemics","phase":"phase_3","mechanism":"Oral antihyperglycemics lower blood glucose levels through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption reduction.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Osmotic-release oral system methylphenidate","genericName":"Osmotic-release oral system methylphenidate","slug":"osmotic-release-oral-system-methylphenidate","phase":"marketed","mechanism":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the synapse.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adults","Narcolepsy"],"catalyst":""},{"name":"PPAR alpha","genericName":"PPAR alpha","slug":"ppar-alpha","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Paclitaxel (Taxane)","genericName":"Paclitaxel (Taxane)","slug":"paclitaxel-taxane","phase":"phase_3","mechanism":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic carcinoma of the ovary","Breast cancer (metastatic and adjuvant)","Non-small cell lung cancer","Kaposi's sarcoma","Gastric adenocarcinoma"],"catalyst":""},{"name":"Pagitane","genericName":"CYCRIMINE","slug":"cycrimine","phase":"marketed","mechanism":"Muscarinic acetylcholine receptor M1","indications":["Parkinson's disease"],"catalyst":""},{"name":"Pemetrexed Phase 2","genericName":"Pemetrexed Phase 2","slug":"pemetrexed-phase-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo (for Ramucirumab)","genericName":"Placebo (for Ramucirumab)","slug":"placebo-for-ramucirumab","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo as Capsules","genericName":"Placebo as Capsules","slug":"placebo-as-capsules","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.","indications":["Control arm in phase 3 clinical trials (specific indication unknown)"],"catalyst":""},{"name":"Placebo every 2 weeks","genericName":"Placebo every 2 weeks","slug":"placebo-every-2-weeks","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo every 4 weeks","genericName":"Placebo every 4 weeks","slug":"placebo-every-4-weeks","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo for Abemaciclib","genericName":"Placebo for Abemaciclib","slug":"placebo-for-abemaciclib","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in phase 3 clinical trials of abemaciclib"],"catalyst":""},{"name":"Placebo-Oral","genericName":"Placebo-Oral","slug":"placebo-oral","phase":"marketed","mechanism":"Placebo produces no pharmacological effect and works entirely through the placebo effect, a psychobiological response to the expectation of treatment.","indications":["Clinical trial control comparator (not a therapeutic indication)"],"catalyst":""},{"name":"Platinol","genericName":"Platinol","slug":"platinol","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Portrazza","genericName":"NECITUMUMAB","slug":"necitumumab","phase":"marketed","mechanism":"Portrazza works by blocking the epidermal growth factor receptor (EGFR) protein, which is involved in cancer cell growth and proliferation.","indications":["Non-small cell lung cancer","Squamous non-small cell lung cancer"],"catalyst":""},{"name":"Prandial Insulin Lispro","genericName":"Prandial Insulin Lispro","slug":"prandial-insulin-lispro","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood sugar levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Quinidine Gluconate","genericName":"QUINIDINE SULFATE","slug":"quinidine-sulfate","phase":"marketed","mechanism":"Quinidine Gluconate works by blocking the M2 muscarinic acetylcholine receptor, which helps regulate heart rhythm.","indications":["Atrial fibrillation","Cardioversion of Atrial Fibrillation","Life-Threatening Ventricular Tachycardia","Malaria","Pseudobulbar affect"],"catalyst":""},{"name":"Raloxifene HCL","genericName":"Raloxifene HCL","slug":"raloxifene-hcl","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ramucirumab (IMC-1211B) DP","genericName":"Ramucirumab (IMC-1211B) DP","slug":"ramucirumab-imc-1211b-dp","phase":"phase_3","mechanism":"Ramucirumab is a monoclonal antibody that blocks vascular endothelial growth factor receptor 2 (VEGFR2) to inhibit tumor angiogenesis and vascular growth.","indications":["Metastatic non-small cell lung cancer (in combination with docetaxel)","Gastric or gastroesophageal junction adenocarcinoma (in combination with chemotherapy)","Metastatic colorectal cancer (in combination with FOLFIRI)","Hepatocellular carcinoma (in combination with atezolizumab)"],"catalyst":""},{"name":"Ramucirumab - SC","genericName":"Ramucirumab - SC","slug":"ramucirumab-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ramucirumab DP","genericName":"Ramucirumab DP","slug":"ramucirumab-dp","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ramucirumab DP (IMC-1121B)","genericName":"Ramucirumab DP (IMC-1121B)","slug":"ramucirumab-dp-imc-1121b","phase":"phase_3","mechanism":"Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.","indications":["Non-small cell lung cancer, gastric cancer, and other solid tumors"],"catalyst":""},{"name":"Rapid Acting Intramuscular Olanzapine","genericName":"Rapid Acting Intramuscular Olanzapine","slug":"rapid-acting-intramuscular-olanzapine","phase":"phase_3","mechanism":"Olanzapine is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist.","indications":["Treatment of schizophrenia","Treatment of bipolar disorder"],"catalyst":""},{"name":"Remternetug (IV)","genericName":"Remternetug (IV)","slug":"remternetug-iv","phase":"phase_3","mechanism":"Remternetug is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Remternetug (SC)","genericName":"Remternetug (SC)","slug":"remternetug-sc","phase":"phase_3","mechanism":"Remternetug is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Reyvow","genericName":"LASMIDITAN","slug":"lasmiditan","phase":"marketed","mechanism":"Reyvow works by binding to the 5-HT1F receptor, blocking pain signals in the brain.","indications":["Migraine"],"catalyst":""},{"name":"Salmon Calcitonin","genericName":"Salmon Calcitonin","slug":"salmon-calcitonin","phase":"marketed","mechanism":"Salmon calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and lower serum calcium levels.","indications":["Paget's disease of bone","Hypercalcemia of malignancy","Osteoporosis in postmenopausal women","Acute bone loss following immobilization"],"catalyst":""},{"name":"Sofetabart Mipitecan","genericName":"Sofetabart Mipitecan","slug":"sofetabart-mipitecan","phase":"phase_3","mechanism":"Sofetabart Mipitecan is a folic acid antagonist that inhibits thymidylate synthase.","indications":["Metastatic colorectal cancer"],"catalyst":""},{"name":"Somatropin (rDNA origin)","genericName":"Somatropin (rDNA origin)","slug":"somatropin-rdna-origin","phase":"phase_3","mechanism":"Somatropin is a recombinant human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes.","indications":["Growth hormone deficiency in children","Growth hormone deficiency in adults","Short stature associated with Turner syndrome","Chronic kidney disease-related growth failure"],"catalyst":""},{"name":"Standard therapy for INCS","genericName":"Standard therapy for INCS","slug":"standard-therapy-for-incs","phase":"phase_3","mechanism":"Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake in muscles.","indications":["Type 2 diabetes","Polycystic ovary syndrome (PCOS)"],"catalyst":""},{"name":"Stimulants","genericName":"Stimulants","slug":"stimulants","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sulfadiazine","genericName":"SULFADIAZINE","slug":"sulfadiazine","phase":"marketed","mechanism":"5-hydroxytryptamine receptor 2A","indications":["Burn Wound Infections","Chorioretinitis","Congenital toxoplasmosis","Encephalitis due to Toxoplasmosis","Minor Bacterial Skin Infections"],"catalyst":""},{"name":"Tadalafil 5 mg","genericName":"Tadalafil 5 mg","slug":"tadalafil-5-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topical Corticosteroid (TCS)","genericName":"Topical Corticosteroid (TCS)","slug":"topical-corticosteroid-tcs","phase":"phase_3","mechanism":"Topical corticosteroids reduce inflammation by suppressing the immune system's response to perceived threats.","indications":["Eczema","Psoriasis","Dermatitis"],"catalyst":""},{"name":"Triamcinolone (Optional)","genericName":"Triamcinolone (Optional)","slug":"triamcinolone-optional","phase":"marketed","mechanism":"Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.","indications":["Inflammatory and allergic conditions (dermatitis, eczema, psoriasis)","Rheumatoid arthritis and other joint disorders","Respiratory conditions (asthma, COPD)","Adrenocortical insufficiency","Systemic lupus erythematosus and other autoimmune diseases"],"catalyst":""},{"name":"Ultra-Rapid Lispro","genericName":"Ultra-Rapid Lispro","slug":"ultra-rapid-lispro","phase":"phase_3","mechanism":"Ultra-Rapid Lispro is a rapid-acting insulin analog that works by stimulating insulin release from the pancreas.","indications":["Treatment of diabetes mellitus"],"catalyst":""},{"name":"Vepugratinib","genericName":"Vepugratinib","slug":"vepugratinib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[^13C4D3^15N]-baricitinib","genericName":"[^13C4D3^15N]-baricitinib","slug":"13c4d3-15n-baricitinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"antiresorptives","genericName":"antiresorptives","slug":"antiresorptives","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"cDMARD","genericName":"cDMARD","slug":"cdmard","phase":"phase_3","mechanism":"cDMARDs work by inhibiting the enzyme peptidyl arginine deiminase, which is involved in the production of autoantibodies.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Juvenile idiopathic arthritis"],"catalyst":""},{"name":"injected insulin","genericName":"injected insulin","slug":"injected-insulin","phase":"phase_3","mechanism":"Injected insulin works by mimicking the action of the body's natural insulin hormone, helping to lower blood sugar levels.","indications":["Type 1 diabetes","Type 2 diabetes"],"catalyst":""},{"name":"insulin lispro LM","genericName":"insulin lispro LM","slug":"insulin-lispro-lm","phase":"marketed","mechanism":"Insulin lispro LM is a premixed insulin formulation that combines rapid-acting insulin lispro with intermediate-acting insulin to provide both mealtime and basal glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"insulin lispro MM","genericName":"insulin lispro MM","slug":"insulin-lispro-mm","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"olanzapine pamoate depot","genericName":"olanzapine pamoate depot","slug":"olanzapine-pamoate-depot","phase":"phase_3","mechanism":"Olanzapine pamoate depot is a long-acting intramuscular formulation of olanzapine, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","indications":["Schizophrenia (maintenance treatment)","Bipolar I disorder (maintenance treatment)"],"catalyst":""},{"name":"olanzapine therapy","genericName":"olanzapine therapy","slug":"olanzapine-therapy","phase":"marketed","mechanism":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Acute agitation associated with schizophrenia or bipolar disorder","Treatment-resistant depression (in combination with fluoxetine)"],"catalyst":""},{"name":"placebo (tadalafil)","genericName":"placebo (tadalafil)","slug":"placebo-tadalafil","phase":"phase_3","mechanism":"Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor, which works by increasing blood flow to the penis to treat erectile dysfunction.","indications":["Erectile dysfunction"],"catalyst":""},{"name":"premeal insulin lispro mixtures","genericName":"premeal insulin lispro mixtures","slug":"premeal-insulin-lispro-mixtures","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"raloxifene HCI and alendronate Na","genericName":"raloxifene HCI and alendronate Na","slug":"raloxifene-hci-and-alendronate-na","phase":"marketed","mechanism":"This combination drug uses a selective estrogen receptor modulator (raloxifene) to reduce bone resorption and a bisphosphonate (alendronate) to inhibit osteoclast-mediated bone loss, together strengthening bone density.","indications":["Postmenopausal osteoporosis prevention and treatment"],"catalyst":""},{"name":"ramucirumab (IMC-1121B)","genericName":"ramucirumab (IMC-1121B)","slug":"ramucirumab-imc-1121b","phase":"phase_3","mechanism":"Ramucirumab is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.","indications":["Metastatic gastric cancer","Non-small cell lung cancer","Advanced or metastatic breast cancer"],"catalyst":""}],"recentEvents":[{"date":"2023-02-01","type":"earnings","headline":"Eli Lilly Reports Fourth-Quarter and Full-Year 2022 Earnings","summary":"Eli Lilly reported fourth-quarter and full-year 2022 earnings, with revenue of $29.5 billion and adjusted earnings per share of $6.23.","drugName":"","sentiment":"neutral"},{"date":"2022-06-28","type":"deal","headline":"Eli Lilly to Acquire Loxo Oncology for $8 Billion","summary":"Eli Lilly announced that it will acquire Loxo Oncology, a biopharmaceutical company focused on developing targeted cancer therapies, for $8 billion.","drugName":"","sentiment":"positive"},{"date":"2021-06-12","type":"regulatory","headline":"FDA Approves Mounjaro for Type 2 Diabetes","summary":"The FDA approved Mounjaro, a glucagon-like peptide-1 (GLP-1) receptor agonist, for the treatment of type 2 diabetes.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPVERlam85djVqVVRYa0JnZzZ5VmN3Vm9TZ1RzZWFwN2toeklwWlhEalgyWC1icjlPQ3ppaWE1eFA0UER5cktILXRfYWpIVWJMMlJ1X2tUcjkxLXVIMnVsYkZnRGdtSUZUVVd4Um9KTXdHLUdxd2REWHdpWE5SUDVkQzVjUFlkOG5RMU1lM0JySjJQMXZ4MXJFQmZlVTJ6M1RIZlZIRkFDRjNHd21ob3VUVnNSU2RnZ3Nxek5EX2ZWTQ?oc=5","date":"2026-04-08","type":"pipeline","source":"BioSpace","summary":"Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma - BioSpace","headline":"Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOTWRKUFFxSkZqdnVqMGlXaEVwaWtLV0dJc21RU2tqeGZpSzhhbEplcWFNUG8zVlk4OE9UVW56VmY0NmJkYjJTTTE0M3oxNlhteE1pNk1IQXhzZzVmTTZYNkVFR2tXMmlDdl84c1c5RHBSQU4wTDFhNzlCVDY5SldIcTBreHg0NnlRR0E0Q0hNM2xMRU43bXMwS0lkbGRKSzhHY2pWVkw2T29zd2w5TEItSW1uQjE5ejVOcmdZNWRQOTZfeFZyUEZucG9jZlZUMk9DMkhacVVPVngyU19ia04tUV9KZTZjM2duUldRN1Yzb2NraTB3VW5mbm9odEpJSEZxS2NvOWlZLThzaTRaWF9uZE9IRmVXd0d2YXVmRUhIOEtIaVItOVJzSGF6M0hDY3dENVhDODQzMzZ6U1BkWWlOdDM5Q2U?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart.com","summary":"Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - Barcha","headline":"Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma Astra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9YSjFiZWF5QzV2THBJMWl6ZnFYNUhTQy1Bd0lOTl90NlE0QjZUMW9oXzVGbHU5QlVvczRKNkNhZTVUVGVGdk9ybkhXbi1nUG5EeUM5d2Vwblp5MXdrZzNFdm93RnUzTWhHQ0E1NVNnbw?oc=5","date":"2026-04-08","type":"deal","source":"medwatch.com","summary":"Eli Lilly pays USD 12.5m to expand Alzheimer's collaboration - medwatch.com","headline":"Eli Lilly pays USD 12.5m to expand Alzheimer's collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxObkwyUGVqQWxCeHdveTU1MVNmOXpPdFQyN0F3SDkzWVdiUmsxSGJnbF8tV19BOWhHcUhGWV81a2U4SnpZYngtMm1oRUl3aUZGNWdiMUpDRk1idHhrak1BYlYtQnRPc1djQmVocnUwc3lKNWVVRFAwSzRFZU94eDdqR1Z0aDRWeXFDS2ZHSlNOVVdhYnN3dUFfb1htdEJldk1faFJxakxB?oc=5","date":"2026-04-07","type":"deal","source":"The Pharma Letter","summary":"AC Immune amends license and collaboration deal with Lilly - The Pharma Letter","headline":"AC Immune amends license and collaboration deal with Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQSkVPVnhIa19PekhBR1dXRUU4LUFkWG1heVVrOVctalc2SmJEVWp0azU2Tk5kOXc5R3hRdE9oYlc1SXpTYjRIWWVuZkhFTklPRnVMcDdmNkJmUzF2RC1QQ2xMY3ZFV0JvblJvWWFwekFBeFpOQlJtOUxYNHduQWpNcnFwR1hTbzgtZW1KV2hzUWF6bWZJSzl6VWRtRGFEZ2NVX1QtVjNYdDNNLVkzVHk0?oc=5","date":"2026-04-06","type":"pipeline","source":"Fierce Pharma","summary":"Eli Lilly takes the court with 150th anniversary campaign to catch Final Four crowd - Fierce Pharma","headline":"Eli Lilly takes the court with 150th anniversary campaign to catch Final Four crowd","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNczRWWVNnNTNwUmtDd2hHdGZFRXNOQzZFcTB4OE1zTEpMQmllQXNRYmJ0RTBfdlhoR011cVd6SG5rbmFac1Bnemo5QlNZb1ZUb3pmNmlTekdOSzVxa2FhZDV4WU9kOTE4M19waGowSUtSNURXUnVoU2dEQ3RadkJSMVBpYjA1c1AtUkplcWNmVlpjSXVfbUstTkRhQQ?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo Finance","summary":"Is Eli Lilly and Company (LLY) The Best Pharma Stock to Invest In Now? - Yahoo Finance","headline":"Is Eli Lilly and Company (LLY) The Best Pharma Stock to Invest In Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQcmN3cU5WS1lTeFVncWFKdS1QLVF0ZWdEUWNRTnUwWFRFOG5fbjFsaXBwZFNCcGs5VDNYbVVpczREZ19hSU1vb2thZGpIUVo4RW5fZlZHdVpjQVJLajYwdHlCNGxsdlhrWV91Zlo5XzIzYkxqbW9kd3lIN2h3NHAwVUU2ejYwVVhISEl1SkcxTW8tdWRzNmp2VGsybVdPT2VOakhHWUhNbFUxQ0h6VE5sRVlhSnFDa1M1NVAwZ2RMVTZfTk5vcWZ3X0J5d1BRYjRwU3JqMjZBa3FZWE5B?oc=5","date":"2026-03-31","type":"deal","source":"PR Newswire","summary":"Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders - PR Newswire","headline":"Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOZ1ByUmp4YWRCRFJ5MDZPTURza3hCbFpBWm9GTHJTVGstTFQySHAtRUFMWWlvckh5dG5KRVZFNWZkWDEwN3lYSWk1VmVjeHBQOFZKYUEwaElGQk54UEs3REw1UUJfUUN3TFdRdzhtNmVYOXNEVFhTeHNTVTExSnZhblBIbmtKM0RGbllpcmhNcUEtWUswdlh5enQ2bWh3T25MUEM0Yi1na1JvSUhZ?oc=5","date":"2026-03-31","type":"deal","source":"WSJ","summary":"Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion - WSJ","headline":"Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPUEFweWxEQzVTeFJ2T2cxS3VDREdTMldDTlEwMW1DMGFMdHV2c0NveE9NRHdkd3phVmduVUxlNzBhOGxsTTFCRkptLV9YSDFOUm5wbk5DYXMwSVZXYXJGbW9zc29uM0h1MFFaZnRvRzlmdmZsTktoeG5WTHV2bEYySnFmMzF6c3V5T0ZCanp3eVVZVU5KMklySURDLVNEWmd2YWNF?oc=5","date":"2026-03-31","type":"deal","source":"Reuters","summary":"Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet - Reuters","headline":"Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOVWhMUDZXUGw0c0l3eWZtVUdZT1kxTUdBMURzWlRKV1VRRkFEc3Rucm1oNlpkUE1wSFlDTWl6OHRtcXhUR2t1b184enRCbHFsTEZDdkZSOXhsU3BfREdodlJWbXdNVUsxeDk5bXN0UUhCOWJRMzBVRVZPZ2pWR3FYWmVJa2tFdk1BajlrOVlRaGFoODZTX0ZJN245THNaakJyNU1hN1BqUdIBrAFBVV95cUxOOE9JZ1d4bktHYnBwa3VWVXZ4enI4YWVjcmdrUTVKZWl3bGlXaTdKcTlDZ2NBTkNpTHBmQ212TkhrZDUybFNYSWZsVENmWC1QTjZHQ1JpeElkdWpCVUZHRTAyNTMyRllTdWNWYlBMUGMyRW5xSlVac3ZmNG12bHNxSlFFdGlOdmhLMk1ncV9aWkw0RFFYQkh5eDVFcGJSOGdmNUxKdlpZVW5mb01a?oc=5","date":"2026-03-29","type":"deal","source":"CNBC","summary":"Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market - CNBC","headline":"Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQT1ZrZklkcDU3RURjUnRIZjV2ME9iQ1d6cTV5TXpQQXdWTVFwRjBlYmUtaUJwdHh1S1dyWDNWdzcwLWFQVTlsUzVjRHBSMWlfWEpubkdhd212VFYyQjl4blBaLWstckVYam8zR3NSa0tFUWVuY1FRSVdycnFtMlQ0eUp1QWlzX3A4RHpNSjRkUXBSZEk?oc=5","date":"2026-03-25","type":"pipeline","source":"statnews.com","summary":"Eli Lilly and the ‘societal obligation’ of GLP-1s - statnews.com","headline":"Eli Lilly and the ‘societal obligation’ of GLP-1s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPcncyWDRrLTNDMWxralJDaFllMFBkdUdKNGs4Tkh0Ylk3TnpEYjgzYWp2RWxMY1dGQXNrZ19uekptVFNBQWZsVU9URDYxZkZ2VWNkUU56X0ZydURaUEptZkg1LWJwT0tGRU92NFJ0NFpLSl94Z25NWkNjTldqZEY3M1EzZ0NlM0pKeXN6RGh1UnpKbGZoRDF2djQ3MVNSc250aXNMMHFzYVh5bTROU2liNEc5T19HTkJFUEhMckRXM25oZw?oc=5","date":"2026-01-30","type":"pipeline","source":"Eli Lilly","summary":"Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility - Eli Lilly","headline":"Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility","sentiment":"neutral"}],"patents":[{"drugName":"Cymbalta","drugSlug":"duloxetine","patentNumber":"","type":"Patent Cliff","expiryDate":"2023-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Prozac","drugSlug":"fluoxetine","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":2500000000},{"drugName":"Retevmo","drugSlug":"selpercatinib","patentNumber":"10584124","type":"Compound","expiryDate":"2038-10-10","territory":"US","annualRevenue":700000000,"genericFilings":[]},{"drugName":"Retevmo","drugSlug":"selpercatinib","patentNumber":"10786489","type":"Formulation","expiryDate":"2038-10-10","territory":"US","annualRevenue":700000000,"genericFilings":[]},{"drugName":"Cialis","drugSlug":"tadalafil","patentNumber":"11975006","type":"Formulation","expiryDate":"2038-12-24","territory":"US","genericFilings":[]},{"drugName":"Cialis","drugSlug":"tadalafil","patentNumber":"12186322","type":"Formulation","expiryDate":"2038-12-24","territory":"US","genericFilings":[]},{"drugName":"Cialis","drugSlug":"tadalafil","patentNumber":"11382917","type":"Formulation","expiryDate":"2038-12-24","territory":"US","genericFilings":[]},{"drugName":"Cialis","drugSlug":"tadalafil","patentNumber":"11666576","type":"Formulation","expiryDate":"2038-12-24","territory":"US","genericFilings":[]},{"drugName":"Retevmo","drugSlug":"selpercatinib","patentNumber":"10786489*PED","type":"Compound","expiryDate":"2039-04-10","territory":"US","annualRevenue":700000000,"genericFilings":[]},{"drugName":"Retevmo","drugSlug":"selpercatinib","patentNumber":"10584124*PED","type":"Compound","expiryDate":"2039-04-10","territory":"US","annualRevenue":700000000,"genericFilings":[]},{"drugName":"Mounjaro","drugSlug":"tirzepatide","patentNumber":"11918623","type":"Method of Use","expiryDate":"2039-06-14","territory":"US","annualRevenue":15530000000,"genericFilings":[]},{"drugName":"Mounjaro","drugSlug":"tirzepatide","patentNumber":"12453758","type":"Method of Use","expiryDate":"2039-07-22","territory":"US","annualRevenue":15530000000,"genericFilings":[]}],"drugCount":209,"phaseCounts":{"marketed":94,"phase_1":17,"phase_3":68,"phase_2":29,"discontinued":1},"enrichmentLevel":3,"visitCount":14,"keyCompetitors":["Pfizer","Merck & Co.","Johnson & Johnson"],"therapeuticFocus":["Diabetes","Oncology","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":65179000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":65179000000,"period":"2025-12-31"},{"value":45042700000,"period":"2024-12-31"},{"value":45043000000,"period":"2024-12-31"},{"value":34124100000,"period":"2023-12-31"},{"value":34124100000,"period":"2023-12-31"}],"grossProfit":54127000000,"grossProfitHistory":[{"period":"2025-12-31","value":54127000000},{"period":"2024-12-31","value":36625000000},{"period":"2023-12-31","value":27042000000},{"period":"2022-12-31","value":21911600000}],"rdSpend":7190800000,"rdSpendHistory":[{"period":"2025-12-31","value":13337000000},{"period":"2024-12-31","value":10991000000},{"period":"2023-12-31","value":9313000000},{"period":"2022-12-31","value":7190800000}],"sgaSpend":11094000000,"operatingIncome":29696000000,"operatingIncomeHistory":[{"period":"2025-12-31","value":29696000000},{"period":"2024-12-31","value":17040000000},{"period":"2023-12-31","value":10325000000},{"period":"2022-12-31","value":8280400000}],"netIncome":20640000000,"netIncomeHistory":[{"period":"2025-12-31","value":20640000000},{"period":"2024-12-31","value":10590000000},{"period":"2023-12-31","value":5240000000},{"period":"2022-12-31","value":6244800000}],"eps":22.95,"epsHistory":[{"period":"2025-12-31","value":22.95},{"period":"2024-12-31","value":11.71},{"period":"2023-12-31","value":5.8},{"period":"2022-12-31","value":6.572215}],"cash":7268000000,"cashHistory":[{"period":"2025-12-31","value":7268000000},{"period":"2024-12-31","value":3268000000},{"period":"2023-12-31","value":2818600000},{"period":"2022-12-31","value":2067000000}],"totalAssets":112476000000,"totalLiabilities":85941000000,"totalDebt":42503000000,"equity":26535000000,"operatingCashflow":16813000000,"operatingCashflowHistory":[{"period":"2025-12-31","value":16813000000},{"period":"2024-12-31","value":8818000000},{"period":"2023-12-31","value":4240000000},{"period":"2022-12-31","value":7585700000}],"capex":-10849000000,"capexHistory":[{"period":"2025-12-31","value":-10849000000},{"period":"2024-12-31","value":-8404000000},{"period":"2023-12-31","value":-7392000000},{"period":"2022-12-31","value":-2985300000}],"freeCashflow":5964000000,"dividendsPaid":-5384000000,"buybacks":-4108000000,"employees":50000,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":2934000000,"ebit":9778000000,"ebitda":10287000000,"period":"2026-03-31","revenue":19799000000,"epsBasic":8.27756,"netIncome":7396000000,"rdExpense":3510000000,"epsDiluted":8.26,"grossProfit":16222000000,"operatingIncome":9778000000},{"sga":3131400000,"ebit":11558800000,"ebitda":12144500000,"period":"2025-12-31","revenue":19292000000,"epsBasic":7.416182,"netIncome":6637700000,"rdExpense":3801500000,"epsDiluted":7.39,"grossProfit":15920300000,"operatingIncome":8987400000},{"sga":2740700000,"ebit":7412000000,"ebitda":7882000000,"period":"2025-09-30","revenue":17600800000,"epsBasic":6.231575,"netIncome":5582500000,"rdExpense":3465700000,"epsDiluted":6.21,"grossProfit":14592500000,"operatingIncome":8386100000},{"sga":2753000000,"ebit":7025400000,"ebitda":7503700000,"period":"2025-06-30","revenue":15557700000,"epsBasic":6.3,"netIncome":5660500000,"rdExpense":3336100000,"epsDiluted":6.29,"grossProfit":13109900000,"operatingIncome":7020800000},{"sga":2468000000,"ebit":5302000000,"ebitda":5765000000,"period":"2025-03-31","revenue":12729000000,"epsBasic":3.073641,"netIncome":2759000000,"rdExpense":2734000000,"epsDiluted":3.06,"grossProfit":10504000000,"operatingIncome":5302000000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1008.8,"previousClose":1015.75,"fiftyTwoWeekHigh":1133.95,"fiftyTwoWeekLow":623.78,"fiftyTwoWeekRange":"623.78 - 1133.95","fiftyDayAverage":939.68,"twoHundredDayAverage":919.05,"beta":0.48,"enterpriseValue":943874310144,"forwardPE":22.8,"priceToBook":28.89,"priceToSales":12.45,"enterpriseToRevenue":13.06,"enterpriseToEbitda":26.06,"pegRatio":1.28,"ebitda":36215001088,"ebitdaMargin":50.1,"freeCashflow":9156599808,"operatingCashflow":20480000000,"totalDebt":43370000384,"debtToEquity":139,"currentRatio":1.5,"returnOnAssets":20.7,"returnOnEquity":107.5,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":29,"targetMeanPrice":1209.14,"targetHighPrice":1500,"targetLowPrice":850,"dividendRate":6.92,"payoutRatio":0.22,"fiveYearAvgDividendYield":0.91,"exDividendDate":1778803200,"insiderHeldPercent":0.2,"institutionHeldPercent":85.4,"sharesOutstanding":891741406,"floatShares":889351539,"sharesShort":7862175,"shortRatio":2.45,"shortPercentOfFloat":0.9,"epsTrailing":28.14,"epsForward":44.28,"revenuePerShare":80.61,"bookValue":34.92,"officers":[{"age":57,"name":"Mr. David A. Ricks","title":"Chairman & CEO"},{"age":47,"name":"Mr. Lucas E. Montarce","title":"Executive VP & CFO"},{"age":51,"name":"Dr. Daniel M. Skovronsky M.D., Ph.D.","title":"Chief Scientific & Product Officer and President of Lilly Research Laboratories"},{"age":56,"name":"Ms. Anat  Hakim J.D.","title":"Executive VP, General Counsel & Secretary"},{"age":40,"name":"Mr. Jacob S. Van Naarden","title":"Executive VP, President of Lilly Oncology & Head of Corporate Business Development"},{"age":null,"name":"Mr. Donald A. Zakrowski","title":"Senior VP of Finance & Chief Accounting Officer"},{"age":50,"name":"Mr. Diogo  Rau","title":"Executive VP and Chief Information & Digital Officer"},{"age":null,"name":"Mr. Michael  Czapar","title":"Director of Investor Relations"}],"industry":"Drug Manufacturers - General","irWebsite":"http://investor.lilly.com/","website":"https://www.lilly.com","phone":"317 276 2000"}}